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I. INTRODUCTION AND REVIEW OF THE LITERATURE 
PURPOSE: 
The studies incorporated in this dissertation are designed 
to add to, using neurochemical techniques, the pharmacological 
evidence that cholinoceptive neurons in the central nervous 
system, under certain conditions, have the ability to modulate 
central adrenergic neurons, reflected as a change in the levels 
of norepinephrine and/or dopamine. 
A. CHOLINOCEPTIVE PATHWAYS OF THE BRAIN: 
The mapping of cholinoceptive neuron$ in the central nervous 
system has till now met with considerable difficulty. Lack 
of specific histochemical or of the more recently developed, 
fluorescent microscopy techniques, has made direct identification 
of cholinoceptive neurons impossible and therefore evidence 
obtained thus far has been indirect. 
The presence of acetylcholine, choline acetylase, and 
' 
acetylcholinesterase has been used to locate cholinoceptive 
neurons (Hebb, 1963 and Koelle, 1963). In addition, Feldberg 
(1957) and Machne (1963) conducted experiments with both 
systemically and topically applied cholinomimetics, cholinesterase 
inhibitors, and cholinergic blocking agents. Stimulation and 
p 
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blocking of recorded responses was thought to indicate presence 
of cholinoceptive neurons. Another approach to the identifi-
cation of central cholinoceptive neurons was to identify 
acetylcholine in the subcellular synaptic fraction from brain 
tissue. Whittaker (1963), DeRobertis(l963), Ryal! (1963), 
and Curtis (1964), were among the first to conduct such experi-
ments. Their findings demonstrated that acetylcholine was 
present in the subcellular fraction containing the synaptic 
vesicles·. Although this type of evidence added support to the 
concept of the role of acetylcholine as a central neurotransmitter, 
it did not however, define specific cholinoceptive pathways. 
Probably the most direct evidence of cholinoceptive pathways 
comes from studies using microelectrophoretic application of 
acetyicholine and cholinomimetic agents directly on central 
neurons while recording extra- or intracellularly. Single 
neurons responding to injected acetylcholine are considered to 
be cholinoceptive. Central mapping of cholinoceptive neurons 
has been done primarily in cat, however, neural and other 
physiological variances may exist between cat and rabbit. As 
these two species are similar in levels of transmitters found 
within specific brain areas, the nerve tracts in these two 
species could be considered as, also similar. Evidence by 
Curtis and Eccles (1958), Curtis et al. (1961), and Curtis 
(1965) demonstrated cholinoceptive nerve paths in the spinal 
cord of cat. Bradley and Wolstencroft (1962 and 1965) added 
evidence of cholinoceptive neurons in the midbrain of cat. 
Curtis and Andersen (1961), Curtis and Davis (1963), and 
p 
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Phillis et al. (1968) demonstrated cholinoceptive neurons in 
cat thalamus. Margules and Stein (1967) reported the presence 
of cholinoceptive synapses in the medial hypothalamic area 
in cat. Curtis et al. (1963) and McLennan (1964) demonstrated 
the presence of cholinoceptive neurons innervating caudate 
nucleus in cat. Curtis and Crawford (1969) reported the 
presence of cholinoceptive neurons in spinal cord, thalamus, 
hypothalamus, basal ganglia, cerebellum, and in cortex. 
Extensiv~ work has also been done on cortical acetylcholine 
content. Krnjevic and Phillis (1963) and Spehlmann (1963) 
demonstrated cholinoceptive nerve tracts in cat cerebral cortex. 
Other central areas where cholinoceptive neurons have been 
located include: the inferior colliculus (Curtis and Koizumi, 
1961); both the mesencephalic and medullary reticular formations 
(Bradley and Wolstencroft, 1962; Salmoiraghi and Steiner, 1963}; 
and the well-documented work of Eccles et al. (1954) and Eccles 
et al. (1956) demonstrating cholinergic innervation of the 
Renshaw cell, which is associated with the spinal motoneurons. 
These studies, although far from providing a complete account 
of the cholinoceptive nerve tracts in the brain, do clearly 
demonstrate that cholinoceptive neurons are widely distributed 
from the spinal cord, rostrall~, through the medulla, midbrain 
thalamus, cortex, and caudate nucleus; in addition to lesser 
structures like the inferior colliculus. Whether these are 
long nerve tracts passing through many areas before terminating 
I 
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on a specific group of cells or short nerve tracts widely 
branching through one particular area is not known. The data 
does show, however, that within each of these areas there are 
nerves the postsynaptic membranes of which are sensitive to 
acetylcholine. Denisenko (1965) has further clarified the 
properties of these cholinoceptive membranes. He has demon-
strated that certain areas of the brain have nicotine ~ sensitive 
cholinoceptive neurons, i.e. cortex, while some areas are 
more muscarine sensitive, i.e. midbrain. More recently, 
Krnjevic (1969) has reported that many more sites in the 
cortex, brainstem, and at other subcortical levels, in the 
cerebellum and in the medulla respond to acetylcholine 
muscarinically rather than nicotinically. Anden et al. (1966) 
in their studies on the effects of induced blockades and 
facilitations of dopamine transmission, found asymmetrical 
syndromes evoked from the intact corpus striatum. Previous 
evidence of Macintosh (1941), Feldberg and Vogt (1948), and 
Burn and Chipman (1951) had shown that the neostriatum con-
tained high concentrations of acetylcholine, choline acetylase, 
and acetylcholinesterase. In addition, Koelle (1954) indicated 
that neostriatal nerves, containing acetylcholinesterase, 
represented true acetylcholine,nerve terminals within this 
structure. These cholinoceptive nerves ascend uncrossed in 
the crus cerebri and in the internal capsule. Shute and Lewis 
(1963) found that there was a severe loss of ipsilateral 
5 
acetylcholinesterase activity in the neostriatum after unilateral 
lesions at the junction between the mesencephalon and the 
diencephalon. From these results, Anden et al. (1966) con-
cluded that in their lesion experiments, neostriatal acetyl-
choline terminals were also removed; and they, in fact, had 
found a reduction of acetylcholinesterase activity in the 
ipsilateral neostriatum much as Shute and Lewis had. It was 
their conclusion that cholinoceptive neurons to the neostriatum 
are functional antagonists of the neostriatal dopamine neurons. 
Schematic diagrams of central cholinoceptive pathways have 
frequently been published. Stein (1970) has proposed a 
cholinoceptive pathway to explain his results on the pharma-
cology of the reward and punishment systems. It was found 
that application of the cholinomimetic agents, carbachol 
and physostigmine, to the medial hypothalamic area restored 
the inhibitory effect of punishment; and usually depressed 
the rate of unpunished behavior, as well. Stein concluded that 
the punishment system has a critical focus in the medial 
hypothalamus and that cholinoceptive synapses are formed at 
this level. 
At best we can state that the telencephalon and midbrain-
diencephalon areas do contain the enzymatic systems for synthesis 
' of acetylcholine, as well as, its degradation. Also contained 
within these areas are cholinoceptive sites which can be 
stimulated by acetylcholine and other cholinomimetic agents; 
6 
and can be blocked b¥ various cholinolytic drugs. It is 
evident that cholinoceptive neurons have wide distribution 
in the mammalian brain. Specific nerve tracts within the 
individual areas, as well as, their role in neuromodulation 
is at present still vague. 
B. CATECHOLAMINE PATHWAYS IN THE BRAIN: 
Unlike the case with the cholinergic system, recent tech-
nology has allowed ·for accurate mapping of the adrenergic 
nerve tracts in the central nervous system, using the fluor-
escence microscopy techniques developed by the Swedish group. 
'Illese techniques not only localize,adrenergic nerve paths, 
but also differentiate quantitatively between norepinephrine 
and dopamine containing neurons. Using histological sectioning, 
individual nerve tracts can be traced from origin to termination. 
~owever, in intact and untreated animals, it is not possible 
to demonstrate the parts of the neuron connecting the nerve 
cell body and the terminal portions. It was found by Anden et 
al. (1966) that by either using a monoamine oxidase inhibitor 
or by making a lesion in the various monoamine neuron systems, 
they were able to demonstrate and map out many of the ascending 
monoamine neuron tracts. These adrenergic tracts have so far 
" 
only been demonstrated in the rat. One would assume with some 
variations that rabbit nerve tracts would closely parallel those 
found in the rat. 
7 
oopamine nerve tracts: 
-
Dopamine nerve cell bodies originating in the substantia 
nigra area of the mesencephalon project rostrally and become 
aggregated in a bundle which ascends just medial and dorsal-
medial to the ventral part of the crus cerebri. .At the level 
of the posterior part of the median eminence the bundle 
turns into the ventral rostral part of the crus cerebri and 
enters and diverges into the retrolenticular part of the 
internal capsule. Running rostrally and dorsally in the 
internal capsule the nerves then ascend in the fibrae capsulae 
internae to innervate the neostriatum (caudate nucleus and 
putamen). It has been found that the neostriatum contains 
close to 80 percent of the brain dopamine, which is correlated 
with the large nerve bundle innervating this region. 
An additional large dopamine nerve tract was also found. 
Cell bodies for these nerves arise in the median/mesencephalon 
region and ascend medially to the crus cerebri into the medial 
forebrain bundle innervating the tuberculum olfactorium and 
the nucleus .accumbens. These nerve bundles run lateral to 
the norepinephrine nerve tracts, also running rostrally, 
and vent~omedially tQ those dopamine nerve fibers which 
innervate the neostriatum. 
' 
Dopamine neurons have also been shown to innervate the 
retina of the eye, with both the cell bodies and terminals 
l'.ocated there. 
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N,_orepinep~rine nerve tracts: 
Initial studies by Dahlstrom et al. (1962), followed by 
the investigations of Dahlstrom and Fuxe (1964 and 1965), 
Anden et al. (1966), and Anden et al. (1965) have demonstrated 
the location of norepinephrine nerve tracts in the central 
nervous system. Using lesion-histochemical techniques, it 
was found that at least 75 percent of the ascending norepinephrine 
neurons originate in cell bodies of the pons and medulla 
oblongata. These fibers innervate various nuclei of the 
hypothalamus including the nucleus dorsomedialis hypothalamic, 
the nucleus paraventricularis, and the nucleus periventricularis 
hypothalamic. These neurons, in addition, innervate the 
thalamus, the preoptic area, the ventral part of the nucleus 
interstitialis striae terminalis, the septal area, the 
arnygdaloid complex, the hippocampal formation, the gyrus 
cinguli, and the pyriform and neocortex. Fibers to the neo-
cortex ascend from the medial forebrain bundle dorsally into 
the tractus diagonalis and then turn caudally into the super-
ficial parts of the white substance. Cell bodies of these 
neurons were found in the pons and the nucleus reticularis 
lateralis of the medulla oblongata. Carlsson et al. (1964) 
had shown that bulbo-spinal norepinephrine neurons also arise 
' 
from these cell bodies. 
An additional 25 percent of the norepinephrine neurons 
innervating the telencephalon have their cell bodies in the 
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formatio reticularis of the mesencephalon. Norepinephrine 
cell bodies have not as yet been found in the neocortex itself, 
although norepinephrine neurons richly innervate this structure. 
Apart from the identification of the specific dopamine 
and norepinephrine nerve tracts coursing through the brain, 
nerve terminals containing either norepinephrine and/or 
dopamine have been found in large numbers within all areas 
of the central nervous system. The density of nerve terminals, 
based on the relative intensity of the histochemically 
developed fluorescence, related directly to the levels of 
norepinephrine and/or dopamine in these structures. 
In conclusion, adrenergic neurons, referring specifically 
to those containing norepinephrine and dopamine, maintain 
their cell bodies in the mesencephalic portion of the brain 
and send their nerve fibers rostrally and caudally innervating 
the spinal cord, diencephalon, telencephalon, and neostriatum. 
Although these studies indicate the major nerve bundles 
contained in the adrenergic system, minor complexities 
associated with these pathways, as well as, the exact neuro-
modulating role of the neurotransmitters, norepinephrine and 
dopamine, are not yet well defined. Present evidence indicate 
that norepinephrine has. an excitatory effect upon central 
" 
neurons (Salmoiraghi, 1966) with influence upon 11 vegetative 11 
functions, i.e. temperature control, neuroendocrine regulation 
Of pituitary function, control of mood, as well as, "non-
10 
vegetative" functions, i.e. control of posture and motor 
activity. In the case of dopamine, however, the effect 
upon central neurons, primarily in the basal ganglia, is 
that of inhibition (Wurtman, 1966 and Salmoiraghi, 1966), 
which is postulated to be antagonistic to the excitatory 
actions of acetylcholine in this region (Anden et al., 1966). 
c. EVIDENCE OF CHOLINERGIC-ADRENERGIC COUPLING: PERIPHERAL 
AND CENTRAL 
Peripheral: 
classification of the postganglionic nerve fibers of the 
entire autonomic nervous system was performed by Dale in 1934. 
He defined autonomic transmission as being either 11 adrenergic 11 
or "cholinergic" based on the neurohumor involved in the 
transmission of impulses from the nerve endings to the effector 
organ. Otto Loewi, in 1921, had already postulated the role 
of acetylcholine in parasympathetic transmission; and Von 
Eular, in 1931, had implicated noradrenaline in sympathetic 
transmission. Thus Dale's classification was not speculative; 
the results of these earlier studies provided supportative 
evidence for his classificatiop. 
The concept of the cholinergic-adrenergic link was advanced 
in 1958 by Burn and Rand, although first mention of mixed 
11 
·cbolinergic and adrenergic postganglionic sympathetic fibers 
,,as made by Dale in his 1934 publication. Dale defined post-
J 
~- qanglionic parasympathetic fibers as "cholinergic" and added 
tbat, "postganglionic sympathetic fibers are predominantly 
.tbough not entirely 'adrenergic'". Dale's inclusion of 
-
cbolinergic fibers within the postganglionic sympathetic supply 
was later confirmed in part by the demonstration of cholinergic 
fibers in the postganglionic supply to the nictitating membrane 
of the cat (Bacq and Fredericq, 1935); to the dog uterus 
(Sherif, 1935); and from the stellate ganglion of the heart 
(Folkow et al., 1948). Koelle in 1955 demonstrated the presence 
of choline acetylase and cholinesterase in adrenergic neurons, 
both of which are involved in synthesis and degradation of 
acetylcholine. Thus, considerable evidence had accumulated 
prior to the hypothesis of Burn and Rand which strongly suggested 
that a cholinergic-adrenergic link existed. It was, however, 
the hypothesis put forth by Burn and Rand in 1958 which advanced 
the role of acetylcholine in the release of adrenergic neuro-
transmitters at the postganglionic sympathetic nerve endings. 
Their postulation was that, "all the postganglionic sympathetic fibers 
• 
have cholinergic mechanisms involved in the release of 
noradrenaline after nerve stimulation, i.e. postganglionic 
sympathetic nerve stimulation first releases acetylcholine 
Which triggers off the mechanism by which noradrenaline is 
liberated from the local tissue stores at the sympathetic 
12 
l' postganglionic nerve endings". Jaju, in 1969, discussed three 
· passible neural mechanisms which would explain the Burn and 
Rand hypothesis. First, that postganglionic fibers might 
release only acetylcholine which would in turn release 
noradrenaline from the adjacent chromaffin cells, a mechanism 
similar to that operating in the adrenal medulla. Secondly, 
the release of acetylcholine by the postganglionic impulse 
might initiate or facilitate the liberation of noradrenaline 
from different nerve fibers. Thirdly, the release of acetyl-
choline from the postganglionic fibers might initiate or 
facilitate the liberation of noradrenaline from the same 
fiber. The second explaination seem most reasonable based 
on previous evidence of mixed cholinergic and adrenergic 
fibers in the postganglionic supply. Whether or not the 
Burn and Rand concept of cholinergic-adrenergic coupling 
will finally be accepted or rejected is still a mute question. 
What seems evident, is that cholinergic-adrenergic coupling 
does exist (cf. Karczmar, 1967). 
One of the earliest observations of cholinergic-adrenergic 
linkage was reported by Brucke in 1935. It was observed that 
a small dose (Spg) of acetylcholine injected at the base of a 
tuft of hairs in cat's tail pI."t>duced piloerection which was 
similar in response to that seen after sympathetic stimulation. 
Coon and Rothman, in 1940, observed results similar to those 
observed by Brucke, using acetylcholine and nicotine. Burn 
13 
et al. (1959) were able to demonstrate that reserpinization 
abolished the piloerection response to both nicotine and to 
a small dose of acetylcholine, reserpine having caused a 
marked decrease in the amount of norepiniphrine, as well as 
the number of chromaffin cells and their granules in the 
skin of the cat's tail. Further support of the role of 
acetylcholine in sympathetic stimulation came from Burn and 
Rand's observations (1962) that hemicholinium, known to block 
the synthesis of acetylcholine, when injected into the base of 
the tufts of hairs caused a slower erection of the tufts 
of hairs to repeated sympathetic stimulation. Untreated 
tufts of hairs were still erect. The autho~s concluded that 
nicotine and small doses of acetylcholine liberated norepinephrine 
which produced the piloerection. This response was greatly 
reduced after blockade of acetylcholine synthesis by hemi-
cholinium and absent after depletion of catecholamine stores 
by reserpine or nerve degeneration. More recently, Rand and 
Whaler (1965) have shown that botulinum toxin, which blocks 
release of acetylcholine from cholinergic neurons, prevents 
piloerection when injected into the base of tufts of hairs in 
cat's tail. The authors concluded that acetylcholine release 
was essential for piloerection,following sympathetic nerve 
stimulation. 
Studies on the nictitating membrane have added evidence 
of a cholinergic-adrenergic link. Bacq and Fredericq (1935} 
....---,. 
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' 
first demonstrated cholinergic fibers innervating the nictitating 
membrane of the cat. Burn and Rand (1960) found that in 
reserpinized cats, contraction of the nictitating membrane 
by stimulation of postganglionic sympathetic fibers was 
potentiated by eserine and blocked by atropine, suggesting 
release of an acetylcholine-like substance by sympathetic 
fibers. Burn et al. (1963) expanded on these findings using 
isolated nictitating membrane preparations. Further, Ambache 
(1951) using botulinum toxin, which blocks the release of 
acetylcholine from cholinergic neurons, observed greatly 
' 
reduced contractions of the nictitating membrane to sympathetic 
stimulation. J'acobowitz et al. (1965) using neuronally 
induced contractions of the nictitating membrane in rabbits 
observed that hemicholinium, which inhibits synthesis of 
acetylcholine, produced a reversible reduction in isometric 
contractions of the nictitating membrane to supramaximal 
tetanic stimulation of the sympathetic postganglionic trunk. 
Similarly, Burn et al. (1963)using hyoscine demonstrated a 
hyoscine resistant component of nictitating membrane contractions 
stimulated postganglionically supramaximally at high frequencies. 
They concluded that the hyoscine resistant component was 
adrenergic in nature, while tbf? hyoscine sensitive component 
was cholinergic. Burn et al. (1963) observed that in 
nictitating membrane of cat treated with hyoscine or atropine, 
contractions to acetylcholine which should have been blocked 
15 
were in fact potentiated with neostigrnine far more at supra-
maximal postganglionic stimulation frequencies below 5/second, 
than above. 
These studies on nictitating membrane indicate that acetyl-
. 
choline is involved to some extent in the modification of 
responses to sympathetic stimulation, although the mechanisms 
involved are unclear from these results. 
Involvement of acetylcholine in response to sympathetic 
stimulation have also been observed on intestine and colon. 
Gillespie and Mackenna (1959 and 1961) observed that in 
reserpinized animals electrical stimulation of the sympathetic 
neurons produced contraction of the colon. It was further 
demonstrated that this effect could be blocked by atropine. 
Burn and Rand (1962) continued these studies demonstrating 
that hemicholinium reduced the inhibitory effects of sympathetic 
stimulation on the isolated colon of untreated animals. In 
addition, they were able to demonstrate reversal of this effect 
with the addition of choline. It was concluded by the authors 
that the reduced adrenergic response was due to the reduction 
in acetylcholine by hemicholinium. Similarly, Rand and Whaler 
(1965) found that botulinum toxin blocked the inhibitory 
effect of nerve stimulation in isolated rabbit ileum. Burn 
' 
et al. (1963) found a biphasic response to low and high 
frequency stimulation on the isolated rabbit ileum with 
mesentary attached. Their results suggested that at lower 
16 
frequency both acetylcholine and norepinephrine were released, 
while at the higher frequencies only norepinephrine was released. 
Their conclusions were based on evidence that hyoscine increased 
the inhibitory effect of nerve stimulation on the ileum at 
low frequencies, but was ineffective at the higher frequencies. 
studies by Sjostrand (1961) on the isolated vas deferens 
of guinea pig, which were previously thought to contain only 
sympathetic innervation, have shown that acetylcholine 
potentiates the response of the vas deferens to electrical 
stimulation. Boyd et al. (1960), Burn and weetman (1963), 
Ohlin and Stromblad (1963), and Riley and Maanen (1962) found 
potentiation of the isolated vas deferens response to electrical 
stimulation using physostigmine and neostigmine. Chang and 
Rand (1960) demonstrated decreased responses of this prep-
aration to nerve stimulation using hemicholinium. Rand and 
Whaler (1965) have additionally shown that botulinum toxin 
abolished the contractions of the vas deferens to sympathetic 
nerve stimulation. These studies suggest a role of acetylcholine 
in the sympathetic response of the vas deferens to nerve 
stimulation. 
Cholinoceptive neurons were reported (Sherif, 1935) to be 
contained in the sympathetic ~upply to the uterus in dog. 
Later, Burn and Rand (1960) reported that in reserpinized cats, 
stimulation of the hypogastric nerve produced contraction of 
the uterus contrasting the inhibitory effect normally observed. 
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'I'h.is stimulant effect, seen in reserpinized cats, was potentiated 
by eserine and blocked by atropine. It was concluded from 
the observations that acetylcholine was involved in the 
excitatory effect on uterus following postganglionic nerve 
stimulation in reserpinized cats. 
Numerous investigators: Ahlquist et al. (1954), Grindly et 
al. (1939), Holtz et al. (1952), and Ottis et al. (1957) have 
demonstrated the ability of epinephrine to contract the spleen. 
Burn and. Rand (1962) found that after stimulation of the post-
ganglionic nerves to the spleen, the volume of the spleen 
either increased or decreased in reserpinized animals. In 
those cases where an increase in volume was observed, it 
was found that eserine would potentiate the response while 
atropine blocked the dilatation of the spleen. In those 
cases where contraction of the spleen was observed, indicated 
by the decrease in volume, eserine was without effect. Atropine 
did have an effect, converting the increase into decrease in 
volume of the spleen. The authors suggested the latter 
response to atropine resulted from incomplete depletion of 
catecholamines by reserpine and subsequent release following 
nerve stimulation producing the observed contraction. Further, 
Bradon and Rand (1961) demonstfated the release of acetycholine-
like substance following postganglionic nerve stimulation in 
reserpinized cats. Using perfusate collected after nerve 
stimulation they observed that this perfusate would cause 
, 
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the isolated guinea pig ileum to contract and atropine was 
found to block the contraction produced by the perfusate. 
Application of neostigmine to the reserpinized cats caused 
an increase in the amount of acetylcholine-like substance 
released upon nerve stimulation. 
Other investigators: Farber (1936), Daly et al. (1961), 
Bradon and Boyd (1961), and Bradon and Rand (1961) have also 
observed sympathomimetic effects of acetylcholine upon the 
spleen in both dog and cat. They found that upon close intra-
arterial injection of acetylcholine into the spleen, contraction 
of the spleen occurred. Reserpinization, dibenzyline or hexa-
rnethonium pretreatment, or nerve degeneration of the sympathetic 
supply were found to block this response. Ferry (1963) has 
further shown that acetylcholine in the presence of atropine 
causes contraction of the spleen. This effect could be blocked 
by bretylium and hexamethonium. A direct excitation of post-
ganglionic adrenergic neurons was therefore suggested for the· 
action of acetylcholine. Bretylium's blocking action, it was 
suggested, was upon the release of catecholamines by acetyl-
choline while hexamethonium's •locking action prevented the 
entry of acetylcholine into the sympathetic neuron (Burn and 
Gibbons, 1964). More recently, Krauss et al. (1970) have 
shown that intra-arterial injection of acetylcholine evoked 
release of norepinephrine from the isolated perfused cat spleen 
and induced antidromic nerve impulses in the splenic nerve. 
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:. Tetrodotoxin, it was shown, prevents release of norepinephrine 
by splenic nerve stimulation and blocked the antidromic 
discharges, however, it did not block the release of norepinephrine 
by acetylcholine. Further, it was shown that a single dose 
of bretylium blocked the release of norepinephrine to splenic 
_nerve stimulation but not release due to acetylcholine. 
Higher concentrations of bretylium were able to block the 
release of norepinephrine by acetylcholine in the tetrodotoxin 
treated spleen. Hemicholinium was shown by Bradon and Rand 
(1961) to block contraction of the spleen produced by stimulation 
of the sympathetic neurons; the addition of choline reverses 
the hemicholinium block. These studies suggest that after 
depletion of acetylcholine, nervous stimulation is ineffective 
in producing the sympathetic response in spleen. In the rat 
spleen, electron microscopic studies have revealed two types 
of vesicles within the terminations of sympathetic neurons; 
one containing dense granules and the other type which was 
not granular but homogeneous (De Robertis and Pellegrino de 
Iraldi, 1961). Following reserpine pretreatment, the granular 
vesicles disappeared. ' It has been shown by autoradiography 
combined with electron microscopy that the granular vesicles 
store 3H-norepinephrine within the terminals of the sympathetic 
nerves supplying the rat spleen. 
Studies on cardiac tissues also favor the cholinergic-
adrenergic concept. Hoffman et al. (1945) studies the effects 
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of acetylcholine upon isolated perfused and atropinized 
hearts from cat, rabbit, and guinea pig. He observed positive 
inotropic and chronotropic effects produced by acetylcholine 
which closely resembled those effects observed following 
sympathetic stimulation. Such evidence suggested release of 
catecholamine-like substances by acetylcholine to produce 
the effects. Their suggestion was confirmed when an epin-
ephrine-like substance was identified in the perfusate. In 
addition, sympathetic denervation of the heart and reserpin-
ization either reduced or blocked the effect of acetylcholine 
(Cabera et al., 1966). Moreover, Hukovic (1960) demonstrated 
that both 2:6 xylyl ether and bretylium, both of which block 
release of catecholamines, blocked the acetylcholine induced 
positive inotropic effect on isolated atria in the presence 
of atropine. Similarly, nicotine has been reported to produce 
a biphasic response on isolated heart and atria of cat, 
rabbit, and guinea pig (Giotti, 1954; Kottegoda, 1935; Leaders 
and tong, 1962; McDowall, 1946; and Trendelenburg, 1960). 
Chiang and Leaders (1965) demonstrated a similar biphasic 
effect of nicotine on isolated rat atria. Kottegoda (1953) 
' 
reported that in atropinized perfused rabbit atria, nicotine 
increased both the force and rate of atrial contraction and 
that hexamethonium, a ganglionic blocking agent, blocked 
these effects to ganglion stimulatory properties of nicotine; 
however, Lee and Shideman, in 1959, found similar responses 
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of nicotine on cat papillary muscles devoid of ganglia. 
Kottegoda's responses to nicotine, it appeared, were not 
due to ganglionic stimulation. Burn and Rand (1958) reported 
that reserpinization or denervation of the rabbit atria, 
depleting the nerve endings of catecholamines, decreased or 
abolished any stimulatory effects of nicotine on the atria. 
These studies suggest that like acetylcholine, nicotine is 
involved in catecholamine mediated responses of the atria. 
studies on the isolated rabbit atria following stimulation of 
sympathetic neurons innervating the atria have shown that 
in normal rabbits a positive chronotropic response was produced. 
However, in reserpinized rabbits a negative inotropic response 
was observed. In addition, eserine potentiated and atropine 
blocked this inhibitory effect (Burn and Rand, 1962). Similar 
studies by Day and Rand (1961) showed that after guanethidine, 
stimulation of postganglionic neurons of cat atria caused 
a cardio-inhibitory effect. Using the same preparation, 
Leaders, in 1963, found in normal cats that stimulation of 
the sympathetic fibers produced a classical cardio-stimulant 
effect followed by a small consistent cardio-inhibitory effect 
' 
and this inhibitory effect could be potentiated by eserine 
and blocked by atropine. In addition, hemicholinium was 
able to block the inhibitory response in both normal and 
reserpinized atria suggesting that acetylcholine is directly 
involved in atrial responses seen after stimulation of 
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sympathetic nerve fibers. 
Evidence of cholinergic involvement in responses of 
blood vessels to sympathetic stimulation has been demonstrated 
by Burn and Dutta (1948) and by Kottegoda (1953). They 
reported that in the presence of atropine, both acetylcholine 
and nicotine produced vasoconstriction in rabbit's ear 
vessels. Moreover, tolazoline, an alpha adrenergic blocking 
agent, reversed the vasoconstriction response of acetylcholine 
and nicotine. From the results, it was concluded that acetyl-
choline released catecholamines from the sympathetic terminals 
which stimulated the beta receptors causing the vasodilatation. 
Burn and Rand in 1958 reported in addition, that in the 
presence of atropine, acetylcholine and nicotine failed to 
produce vasoconstriction of the rabbit ear vessels following 
reserpinization or denervation. Hukovic (1960) further 
demonstrated that 2:6 xylyl ether and bretylium both blocked 
the vasoconstrictor effect suggesting that the vasoconstriction 
response to acetylcholine is mediated through norepinephrine. 
Stimulation of postganglionic sympathetic neurons supplying 
rabbit ear vessels is known to produce vasoconstriction of 
' the vessels. Horton and Rand (1962) demonstrated that the 
vasoconstriction response to postganglionic nerve stimulation 
caused a decrease in blood volume followed by vasodilitation. It 
was also shown that eserine potentiates this vasodilatation and that 
atropine blocks this response. Similarly, Burn and Rand (1962) 
reported that administration of hemicholinium blocked the vasoconstrictor 
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. effect of nerve stimulation on rabbit ear vessels and that 
the hernicholinium block co~ld be reversed by choline administration. 
It was concluded that nerve stimulation released ACh which in 
turn released norepinephrine producing the vasoconstriction. In 
support of their conclusions, evidence was presented showing that 
perfusate collected from the ear vessels contained a substance 
which caused the leech muscle to contract, presumably acetylcholine. 
More recently, Rand and Varma (1970) demonstrated that low doses 
of acetylcholine, muscarine, and pilocarpine enhanced the vaso-
constriction of the rabbit ear artery in response to sympathetic 
I 
nerve stimulation, while high doses depressed these effects and 
atropine was shown to block this depressant effect. In 
addition, it was reported that acetylcholine and methacholine 
enhanced the vasoconstrictor response to injected norepinephrine. 
It was suggested from these results that these cholinomimetic 
drugs act to facilitate or impair (depending upon dosage) the 
release and uptake of norepinephrine from adrenergic terminals 
associated with rabbit ear artery. Loffelholz and Muscholl 
(1970) demonstrated, using isolated rabbit atria perfused 
with Tyrode solution containing amphetamine, that electrical 
" 
stimulation of the right postganglionic sympathetic neurons 
caused release of norepinephrine which could be markedly 
decreased by simultaneous stimulation of vagal nerves. The 
results, it was suggested, indicate an inhibitory cholinergic-
adrenergic interaction. 
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Using hind limb vessels in dog, Burn in 1932, demonstrated 
that stimulation of sympathetic neurons to the hind limb produced 
vasoconstriction in some experiments and vasodilatation in 
others. Bulbring and Burn in 1935 showed that some of these 
fibers were cholinoceptive in nature. Burn (1961) and Mccubbin 
(1961) using guanethidine, which blocked norepinephrine 
release, found that sympathetic nerve stimulation to dog hind 
limb produced vasodilatation which could be blocked by atropine. 
Bernard and Schaepdryver (1964) were able to demonstrate that 
electrical.stimulation of the nerve supply to dog hind limb 
produced vasoconstriction that in atropinized dogs was potent-
iated by anticholinesterases. Cholinergic involvement in 
sympathetic stimulation of dog hind limb vessels seemed 
indicated. 
Studies using perfused accessory cephalic vein of the dog 
(Rice and Long, 1966) demonstrated that acetylcholine injected 
into the perfusing fluid produced vasoconstriction of the 
vein which could be inhibited by pretreatment with reserpine 
or phentolamine and could be potentiated with cocaine. Further# 
the venous effluent following acetylchoiine could relax the 
' 
chick rectal caecum and this effect could be blocked by 
pronethanol, an adrenergic beta blocker. Hexamethonium had 
no effect on the vasoconstriction produced by acetylcholine 
ruling out a ganglionic mechanism for the response. In 
reserpinized animals, tyramine has been shown by Chandra et al. 
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• ~ (1965), Maxwell et al. (1959), and Trendelenburg (1961) to 
produce a fall in systemic blood pressure. This depressor 
effect is potentiated by eserine and blocked by atropine 
suggesting acetylcholine involvement. 
From the volume of evidence reviewed, one would be hard 
pressed to doubt the existence of a cholinergic-adrenergic 
linkage in the Autonomic Nervous System. One might, and 
rightfully so, question under what conditions such a coupling 
phenomena functions and for what purpose. Hopefully future 
studies will enlighten us on these points. 
Yet, there are counter arguments to acetylcholine's role 
in synaptic transmission as proposed by Burn and Rand (Karczmar, 
1969), as well as, other concepts involving acetylcholine 
in synaptic transmission. Koelle (1963) suggested a double 
step release of acetylcholine from nerve terminals. Acetyl-
choline released in the course of the first step would then 
impinge upon· the presynaptic nerve terminal, this second 
step initiating mass liberation of the transmitter. 
At one time, Feldberg (1948) suggested that cholinergic 
transmission may never embrace two successive relays, and 
' 
that the cholinergic mechanism is followed by a noncholinergic 
step. 
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central: 
Evidence of cholinergic-adrenergic coupling within the 
central nervous system can be considered as sparse compared 
to the volume of evidence dealing with the peripheral nervous 
system. It should not be inferred from this that cholinergic-
adrenergic coupling does not exist within the central nervous 
system, but rather it attests to the difficulty in obtaining 
meaningful data from so complex and inaccesible a system. 
Most of the evidence reported has come from recent studies. 
Srimal et al. (1969) demonstrated, using intracerebroventricular 
injections of choline in anesthesized dogs, that a biphasic 
blood pressure response was observed~ an initial hypertensive 
phase followed by a delayed hypotensive phase. The initial 
hypertensive phase was felt to be due to choline and was 
blocked by atropine. The delayed hypotensive phase resembled 
that observed after intracerebroventricular injection of 
norepinephrine. This hypotensive phase was abolished by prior 
reserpinizatio~ and blocked by pronethalol and INPEA, both 
adrenergic beta receptor blocking agents. It was concluded 
that the intracerebroventricul~rly injected choline stimulated 
the central release of norepinephrine to cause the hypotensive 
phase. 
Additional evidence reported by Przuntek and Philippu (1971) 
demonstrated that, in vitro, acetylcholine in the presence 
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of calcium accelerated the release of norepinephrine from 
intact hypothalamic cells. In a similar preparation, Philippu 
and Przuntek (1967) demonstrated that acetylcholine releases 
norepinephrine from the subcellular norepinephrine storing 
vesicles of the hypothalamus. Philippu (1970) further 
demonstrated that in cat hypothalamus labelled with 14C-
norepinephrine, the radioactive norepinephrine was found 
to be taken up by the synaptosomal fraction. Moreover, during 
perfusion of the third ventricle of cat, labelled norepinephrine 
was found to be spontaneously released from the hypothalamus 
into the perfusing fluid. Addition of acetylcholine in the 
presence of calcium enhanced the release of labelled norepinephrine 
as did electrical stimulation of the hypothalamic nuclei. 
Van Meter (1969) and Van Meter and Karczmar (1971) studying 
central EEG responses in rabbits to anticholinesterase agents 
confirmed the finding of Longo and Silvestrini (1957) that 
EEG recruitment could be blocked with eserine, and demonstrated 
that the pretreatment with reserpine abolished the anti-
recruitment effects of eserine and that the replenishment 
of the norepinephrine levels fellowing DOPA administration 
restored blocking action of eserine on EEG recruitment. In 
addition, this eserine block could not be obtained following 
depletion of the norepinephrine levels by alpha-methyl-para-
tyrosine, but with replenishment of the norepinephrine stores 
following administration of DOPA and a monoamine oxidase 
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inhibitor, eserine was again able to block the EEG recruitment. 
similarly, Karczmar and Longo (1969) and Karczmar et al. (1970) 
observed in reserpinized rabbits that eserine produced EEG 
and behavorial syndrome characteristics of the paradoxical 
sleep phenomena. Neither eserine nor reserpine alone 
produced these effects. It was concluded that an interplay 
between eserine and reserpine existed and such interplay 
was necessary for the paradoxical sleep phenomena to occur 
in rabbits. 
These data, although few in numbers, clearly point to 
possible existence of a cholinergic-adrenergic coupling phenomena 
within the central nervous system. Present methodology, i.e. 
fluorescence microscopy, microelectrophoretic drug application, 
and ion-exchange chromatography, provides more exacting 
results allowing for a clearer interpretation of the results. 
The lack of sufficiently refined experimental methodology 
seems to be a major hindrance of earlier studies. The concept 
of central cholinergic-adrenergic coupling is even more 
convincing if one reflects on the diffuse neural network 
we presently understand as comrrising the central nervous 
system. Unlike the more well-defined Autonomic nerve network, 
the Central network, with its opposing cholinergic and 
\ 
adrenergic systems, could employ such a coupling phenomena 
as a neuromodulating mechanism designed to maintain homeo-
static bal~nce within the central nervous system. 
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ACTIONS OF PERTINENT DRUGS: 
l-phenyl-3-hydrazinobutane (JB835) 
-
H ~ H ~ structure: I I 
c c c N-Ntt2 ~ 1. I H 
CH3 
l-phenyl-3-hydrazinobutane (identified in the text by the 
more common nomenclature - JB835}, one of a series of compounds 
synthesized by John Biel, was found to be a potent inhibitor of 
monoamine oxidase, the enzyme responsible for degradation of 
dopamine and norepinephrine as well as of epinephrine and serotonin. 
Spector et al. (1959) demonstrated in vitro that JB516, also a 
monoamine oxidase inhibitor, and JB835 were equally potent 
and completely inhibited the activity of monoamine oxidase 
-5 
at a concentration of 1 X 10 M within 30 minutes. 
Studies with JB835 indicated that a single dose (3mg/kg, iv) 
produced 95 percent inhibition of monoamine oxidase in rabbit 
brain homogenates within 30 minutes, the inhibition lasting 
for 48 hours, subsequently, a 75 percent inhibition lasted 
for the next 48 hours. The su~cutaneous route required longer 
periods for the peak effect to occur. Serotonin was observed 
to rise by 50 percent within 15 minutes while accumulation 
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for one-half turn-over of the brain pool of serotonin is about 
15 minutes, while that of norepinephrine is several hours. 
The observed rapid rise in brain serotonin following JB835 
suggests that it readily penetrates the brain, as does JB516. 
similar observations were made by Brodie et al. (1960). 
Although JB516, the hydrazine analogue of amphetamine, 
in doses of lOmg/kg,iv, or higher produced immediate 
amphetamine-like central excitation and mydriasis, JB835 
in doses up to 40mg/kg,iv produced no such effects. 
These results demonstrate JB835's ability to inhibit 
monoamine oxidase in brain in rabbits and to increase brain 
amine levels without producing central excitation typical of 
many monoamine oxidase inhibitors, i.e. JB516. 
3,4-DL-Dihydroxyphenylalanine (DOPA) 
Structure: HO 
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DOPA is synthesized in vivo within chromaffin cells and 
certain neurons by the hydroxylation of tyrosine (Nagatsu et 
al., 1964; Wurtman, 1966). DOPA is not readily abundant in 
blood or tissues in vivo (Anton and Sayre, 1964), suggesting 
that it is rapidly metabolized probably by decarboxylation. 
When injected, however, DOPA is capable of penetrating into 
the brain from the blood (Carlsson et al., 1958). Wurtman 
et al. (1970) injected small doses (2.5 mg/kg) of 14C labelled 
DL DOPA intraperitoneally into mice. It was found that the 
level of 14C-catecholamines in the whole carcass reached 
a peak within 20 minutes and that o-methylation was the main 
catabolic pa~h of the labelled DOPA in the periphery. Almost 
all of the 14C label was found with the dopamine fraction, 
a much smaller amount with the norepinephrine fraction, and 
essentially none incorporated into protein. Further, it was 
found that only 0.01 percent of the injected label was found 
in brain 20 minutes following the injection of the labelled 
DOPA as 14C DOPA and 14C dopamine, the remainder of the label 
recovered in the periphery. However, Bartholini and Pletscher 
(1968) and Persson and Waldeck (1968) demonstrated, using 
' larger doses of DOPA, that norepinephrine levels as well as 
dopamine levels were elevated in the brain of rats and mice. 
/ 
Similar observations were made in rabbits following DOPA 
pretreatment by Glisson and Karczmar (1970}. 
Behaviorally, DOPA produces central excitation which is 
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increased by previous inhibition of monoamine oxidase (Carlsson 
et al., 1960) as well as stimulate the spontaneous motility 
{Carlsson et al., 1957). 
Diisopropylfluorophosphate (DFP) 
structure: 
DFP's mechanism of cholinesterase inhibition is that of 
phosphorylating and thereby inactivating "serine enzymes", i.e. 
acetylcholinesterase and butrylcholinesterase. Since acetyl- · 
cholinesterase is found in erythrocytes, at parasympathetically 
innervated effector organs (smooth muscle; glands}, at the 
skeletal muscle end-plates, at autonomic ganglia, and in the 
central nervous system, administration of the lipid soluble 
DFP inhibits at these sites the action of acetylcholinesterase, 
which is to hydrolyze the neurotransmitter, acetylcholine. 
When the cholinesterase activity is reduced by one-half, 
symptoms of accumulation of ac"3tylcholine begin to appear, i.e. 
salivation, lacrimation, defecation, and urination. Further 
reduction of the cholinesterase activity to below 10 percent 
normal activity will eventually result in death, usually 
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aue to respiratory failure, caused in part by neuromuscular 
paralysis of the intercostal muscles and diaphram, and in 
part by central depression (Goldstein et al., 1969). DFP's 
ability to penetrate the central nervous system is due to 
its high l·ipid solubility which allows for easy entry into 
the brain. Regarding the inhibition of various cholinesterases, 
-7 -8 
in low concentrations (10 - 10 ) DFP preferentially inhibits 
butrylcholinesterase as does physostigmine at low doses. 
-6 
At high doses (10 ), however, DFP readily inactivates acetyl-
cholinesterase: a dose of 2.5 mg/kg being more than sufficient 
for acetylcholinesterase inhibition (Koppanyi and'Karczmar, 1951). 
Grieg and Holland (1949) and Greig and Mayberry (1951) reported 
that the permeability of the blood brain barrier of the 
central nervous system is increased by cholinesterase inhibitors. 
Fuchsine, barbital, and choralose were shown to have increased 
entry into the brain following administration of cholinesterase 
inhibitors. Such evidence is relevant since DFP could 
alter the blood brain barrier allowing quaternary drugs 
entry into the brain. Care must be taken to assure that 
the effects of quaternary drug~ in the presence of DFP represent 
only peripheral responses (Albanus, 1970: Wills, 1970). 
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Atropine sulfate (AtSO ) 
.4 
H 
Structure: 
c---CH2 CH OH l+ I I 2 
HNCH3 CH-0-CO-CH l I 
Hf---~ CH 2 
2 
The mu~carinic blocking action of the tertiary atropinic 
agents is highly specific in as much as the nicotinic sites 
such as the ganglia and neuromuscular end-plates are not 
appreciably blocked, even by doses greater than those necessary 
to produce complete blockade of susceptible muscarinic 
receptors. The mechanism of action of the muscarinic blocking 
agents, i.e. atropine sulfate, atropine methyl nitrate, etc., 
involves a decrease in the response of normally sensitive 
tissues, i.e. peripheral vascular smooth muscle, gastro-
intestinal and genitourinary ~mooth muscle, constrictor and 
ciliary muscles of the eye, as well as, secretions from 
glands such as bronchial, salivary, and gastric, to acetyl-
choline. The decreased response may be due to impaired 
access of acetylcholine to the muscarinic receptors. The 
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block is competitive in type since very large doses of acetyl-
choline may "break through" and produce a muscarinic effect. 
The primary central nervous system effect at moderate doses 
is sedation, while at toxic ~oses excitation predominates 
(Sutherland, 1970). Further studies using dogs (Albanus, 1970) 
indicate that atropine (0.5-2.5mg/kg) produced a decrease 
in general locomotor activity and ataxia, marked tachycardia, 
depressed salivation, marked mydriasis; Albanus was also 
able to produce complete inhibition of the normal blood 
pressure response to acetylcholine. Of importance was that 
the centrally induced ataxia seen with atropine could also 
be observed with atropine methyl nitrate, the quaternary 
atropinic, but only using 100 times the dose of atropine. 
This is co~sistent with the observations that massive doses 
of quate;r-nary compounds will eventually "break through" the 
blood brain barrier and enter the central nervous system. 
Hingtgen and Aprison (1970) reported that high doses 
(0.8mg/kg) of a~ropine blocked behavorial excitation in rats, 
which they had previously shown to be correlated with central 
acetylcholine concentrations (~prison et al., 1968). Comparable 
doses of atropine methyl nitrate had no effect. Polak and 
Meeuws (1966) demonstrated that atropine caused a release 
of acetylcholine from isolated cerebral cortex in rats, 
which Hingtgen and Aprison considered was in part responsible 
for the block of behavorial excitation observed by them 
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following atropine. 
In addition to the above effects, atropine is able to offer 
some amount of protection from organophosphorus poisoning. 
Johnson and Stewart (f970) reported that in rabbits, atropine 
(l.2mg/kg,iv) was able to reverse the respiratory arrest 
produced by sarin without affecting the changes in nerve-
muscle function. Douglass and Matthews (1952) reported that 
of atropine's actions on anticholinesterase poisoning, the 
most important one was the central effect in protecting 
the medullary respiratory center fran the depressant effect 
\ 
of anticholinesterases. 
These results indicate that a dose of 2.0mg/kg of atropine 
is adequate to produce blockade of peripheral muscarinic 
sites, as well as exert blocking actions within the central 
nervous system upon the cholinoceptive sites. 
Atropine methyl nitrate (ATMN) 
H CH . H2C c I+ I 2 TH20H N03 Structure: CH3N CH3 CH-0-CO-CH I . I 
' 
HC c CH2 2 H 
The actions of atropine methyl nitrate in the periphery 
are identical to those described for atropine sulfate, 
although ATMN at the same concentration as atropine sulfate 
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is more potent in its ability to block peripheral muscarinic 
sites than atropine, probably due to atropine's wider central 
and peripheral distribution as opposed to only the peripheral 
distribution for ATMN (Goldstein et al., 1969). The quaternary 
structure of ATMN excludes it from easy access into the 
central nervous system, although entry can occur using 
high doses, i.e. 100 times atropine's dose (Albanus, 1970). 
Although central protection is of greatest importance 
against respiratory failure in organophosphorus poisoning, 
Coleman et al. (1963) have reported some protection against-
organophosphorus poisoning with ATMN alone or with an oxime, 
suggesting that the peripheral sites contribute to the 
toxicity. 
The evidence indicate that a dose of 2.0mg/kg of ATMN is 
sufficient for blockade of peripheral muscarinic sites but 
this low dose is incapable of entry into the central nervous 
system without alteration of the normal entry mechanisms 
(Albanus, 1970; Wills, 1970). 
Although recent evidence (Van Meter, 1969; Van Meter and 
Karczmar, 1970; Philippu, 1970' indicate anticholinesterase 
effects upon central norepinephrine levels, the effects of 
anticholinesterases upon central dopamine levels are unknown. 
With this background of information, the importance of an 
investigation into the effects of anticholinesterases on 
~ 
r 
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dopamine, as well as norepinephrine levels seemed indicated. 
AS norepinephrine is formed by the hydroxylation of dopamine, 
it would be inconsistent to consider that norepinephrine 
was affected by anticholinesterases but not dopamine. 
The initial purpose, therefore, was to determine whether 
the anticholinesterase, diisopropylphosphofluoridate (DFP), 
'would produce a demonstrable effect upon the levels of 
dopamine/and or norepinephrine in rabbit brain. Midbrain-
diencephalon and the caudate nucleus were selected, for their 
high amine contents, as the areas to be examined. 
Following these initial experiments, additional studies 
would be carried out to clarify any observed responses. 
It would be important to determine whether the effects upon 
norepinephrine and dopamine levels due to DFP were dose 
dependent. In addition, the ability of atropinic agents, 
both tertiary and quaternary, to block the DFP-induced effects 
should be investigated. 
Upon completion of these experiments, it would be necessary 
to define more precisely the specific brain areas involved. 
' Using localized brain area, i.e. midbrain, thalamus, 
hypothalamus, and hippocampus, the information obtained 
would indicate whether the responses to DFP, as well as the 
sites of atropinic blockade, were localized or widespread. 
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Finally, with regard to norepinephrine and dopamine, studies 
using intraventricular injections of DFP would provide information 
as to the central responses to DFP, which should closely 
mimic those responses seen following peripheral blockade by 
the quaternary atropinic, AT.MN. 
Since the effects upon norepinephrine and dopamine levels 
are postulated to be due to the elevated acetylcholine 
levels resulting from DFP's inhibition of cholinesterase 
activity; the inhibition of cholinesterase activity and the 
resulting elevation of acetylcholine levels should be demon-
strated. Therefore, assay of the percentage inhibition 
of the cholinesterase activity produced by DFP, as well 
as bioassay of the levels of acetylcholine will be carried 
out following the various drug pretreatments. 
These experiments will provide pertinent information as 
to the neurochemical changes associated with the cholinergic-
adrenergic coupling phenomena • 
• 
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II. MATERIALS AND METHODS 
&aterials: 
New Zealand albino rabbits were chosen as the biological 
material because of their readily availability, their ease 
of handling, and the availability of pertinent data obtained 
both in this laboratory and elsewhere. Only male animals were 
used in these experiments to avoid possible estrus effects 
on the results. In some of the experiments two brain areas 
were used, the midbrain-diencephalon and the caudate nucleus. 
The caudate nucleus in rabbit is of sufficient size and 
amine content to allow individual determinations. In other 
experiments four individual brain areas were used: the 
thalamus, the hypothalamus, the midbrain, and the hippocampus. 
In these latter experiments tissue samples were pooled from 
two rabbits to obtain a more accurate determination of the 
amine levels in these tissues. The weight of the rabbits 
was 2.5 + 0.5 kilograms. All animals were housed in individual 
rabbit cages located within the animal facilities. The room 
temperature was maintained at 74 degrees Fahrenheit and 
food and water was provided to the animals ad lib. 
Drugs and dosage: 
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l-phenyl-3-hydrazinobutane (JB835) was administered at a 
constant dose of 6.0mg/kg whenever used alone or as part 
of a drug regime. The drug was dissolved in physiological 
saline and administered via the intraperitoneal route. 
3,4-DL Dihydroxyphenylalanine (DOPA) was administered 
at a constant dose of SOmg/kg when used either alone or as 
part of a drug regime. The drug, as the hydrochloride, was 
heated in physiological saline until dissolved, allowed to 
cool, and administered via the intraperitoneal route. Although 
the DL form of this drug was used as it is readily available 
in this form it has been demonstrated that only the L form 
is capable of conversion to dopamine by DOPA decarboxylase 
(Cooper et al., 1970). The functional dosage would there-
fore be 25mg/kg. 
Diisopropylfluorophosphate (DFP) was administered in three 
different dosages in the various experiments. Although in 
one experimental series l.Omg/kg was used to demonstrate the 
dose effect relationship, the 2.Smg/kg dosage was the primary 
dose used. The DFP for these two dosages was prepared in 
peanut oil at a stock solution' concentration of 1 percent. 
Both the 1.0 and 2.Smg/kg dosages were administered in the 
neck region via the sub-cutaneous route. LD 50 doses were 
determined on mice with each new DFP preparation to ensure 
constant potency from preparation to preparation. The third 
dose of DFP used was 200pg. This dosage was prepared in 
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physiological saline and injected via the intraventricular 
route within 15 minutes from preparation. The concentration 
of the stock solution was 2.0mg/ml from which a lOOpl volume 
(200µg) was used for the injection into the ventricle. DFP 
prepared in saline was found to have a pH of 3.61. Injection 
of such a low pH solution into the ventricle is definitely 
not physiological. However, due to the rapid decomposition 
of DFP at the more basic pH's, no attempt was made to adjust 
the pH of the DFP solution to that of cerebral spinal fluid 
contained in the ventricle. Feldberg (1958) in his studies 
of intraventricular injection of DFP into cats, was made no 
mention of any pH correction. It was felt, however, ·that the 
effects, if any, due to the low pH should be controlled. 
Therefore, in the sham control rabbits receiving physiological 
saline in place of DFP, the pH of the saline was adjusted 
to that of the DFP solution, 3.61. 
Atropine sulfate (AtSO ) was used at a dosage of 2.0mg/kg or 
4 
4.0mg/kg when used as part of a drug regime. The drug 
was dissolved in physiological saline and administered via 
the intraperitoneal route. ' 
Atropine methyl nitrate (AT.MN) was used at a constant 
dosage of 2. Omg/kg when used as a part of a drug regime·. 
The drug was dissolved in physiological saline and administered 
via the intraperitoneal route. 
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~eguence of drug administration: 
Eight major drug administration sequences were used in 
these experiments; their sequences and their relationship to 
the sacrifice time can be described as follows. (1) Animals 
were sacrificed two hours after receiving either JB835 alone, 
DOPA, or AT.MN alone. (2) Animals were sacrificed one hour 
following DFP given alone at the dose of either 1.0 or 2.5 
mg/kg. (3) Animals receiving JB835 and DOPA were given JB835 
followed after 1 hour by DOPA and sacrificed 2 hours following 
DOPA (3 hours after JB835). (4) Animals receiving either 
JB835-, DOPA-, or ATMN with DFP were given DFP one hour 
following the administration of one of the other members 
of the combination and sacrificed 1 hour after the administration 
of DFP (2 hours after JB83~ DOPA, or AT.MN). (5) Animals 
receiving the JB835-DOPA-DFP combination were given JB835 
first followed at 1 hour intervals by DOPA and by DFP; they 
were sacrificed 1 hour later (3 hours after JB835). (6) 
Animals receiving JB835-DOPA-DFP combination with either 
AtSO or AT.MN were given JB835 followed at 1 hour intervals 
4 
by DOPA and either AtSO or ATMN; DFP was administered 15 minutes 
4 
later and the animals were sacrificed 1 hour later (3 hours 
15 minutes after JB835). (7) Animals receiving JB835-AtSO 
4 
DFP combination were given JB835 followed after 1 hour by 
AtSO~and after 15 minutes by DFP; they were sacrificed 
1 hour later (2 hours 15 minutes after JB835). (8) The last 
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group of animals were given JB835 followed at hourly intervals 
bY DOPA and by DFP l.Omg/kg; they were sacrificed at intervals 
of 1 hour, 2 hours, and 3 hours after DFP. 
All of these dose cycles were adjusted so that animals 
were always sacrificed at 2 P.M. + 30 minutes to avoid 
possible circadian effects on the results. In the case of the 
animals receiving AtSO or ATMN, the slightly longer dose 
4 
cycle was found to be without effect on the amine levels. 
Isolation and removal of tissue samples: 
Following decapitation the caudate nucleus and midbrain-
diencephalon were isolated and removed according to the 
following procedure. First, the left and right cerebral 
hemispheres were separated and cut was made through the 
left and right cerebral peduncles, liberating the left and 
right hemispheres. By carefully teasing the hippocampus 
back, the entire caudate nucleus from head to tail was exposed. 
Using a pair of toothed iris forceps, the caudate nucleus 
was teased away from the ventricular wall. 
The midbrain-diencephalon.,region is then easily obtained 
by transecting the lower brain stem on a line from the 
caudal end of the inferior colliculus to the rostral end 
of the pons, thereby isolating the midbrain-diencephalon from 
the rest of the brain stem. Following removal of this brain 
part, any vascular or connective tissue still connected 
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to the parts was removed and the parts rinsed free of blood 
with distilled water. 
For those studies in which individual brain parts were 
used, their removal was as follows: Hippocampus: the hippo-
campus was rolled back and teased away from the neocortex 
after the hemispheres have been removed from the rest of the 
brain. Midbrain: the midbrain-diencephalon section was placed 
on a glass plate and a sagittal cut was made down the center 
of the tissue. A transverse cut was then made along the 
caudal border of the thalamus, separating the midbrain from 
the diencephalon. Thalamus and hypothalamus: the diencephalon 
was placed with the exposed inner surface dorsally positioned 
on the glass plate. The border between the thalamus and 
hypothalamus was found and a transverse section made separating 
the dorsal thalamus from the more ventral hypothalamus. 
These dissections were easily made and identical areas were 
always removed from the various brains sampled. 
Catecholamine determinations: 
The method for the determination of norepinephrine and 
dopamine from a single tissue was described in part by 
' 
Carlsson and Waldeck (1958); Bertler et al. (1958); and 
Carlsson and Lindqvist (1962). This method utilizes the 
principles of ion-exchange column chromatography in .the 
purification and separation of norepinephrine and dopamine. 
Modifications of the original method were made for use in 
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these studies. The procedures used are as follows. 
Extraction of amines: 
Immediately following removal, each tissue was weighed and 
placed in a 15 ml ground glass hand homogenizer containing 
a.o mls. of 0.4 N. perchloric acid. The homogenizer and acid 
were prechilled and kept in an ice bath at all times to 
minimize destruction of the amines by temperature. Next, the 
tissue was thoroughly homogenized and the homogenate poured 
into a 12 ml. thick-walled conical centrifuge tube, also in 
an ice bath. An additional 3.0 mls. of the perchloric acid 
were then added to the homogenizing vessel as a wash. After 
moving the pestle up and down the vessel several times, the 
wash volume was poured into the homogenate. 
At this time recovery standards are prepared. 4.0 mls. of 
a homogenate made from brain tissue and perchloric acid were 
added to each of two 12 ml. centrifuge tubes. One tube 
contained the standards and the other served as its tissue 
blank. To the standard tube, 3.0 mls. of the perchloric acid 
was added. Next, one ml. of norepinephrine standard at a 
' concentration of 1 µg/ml. was added to the standard tube, 
as was one ml. of dopamine standard of the identical concen-
tration. To the tissue blank tube, 5.0 mls. of the perchloric 
acid was added. These two tubes, one containing the homogenate 
plus standards and the other the homogenate alone, were treated 
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identically with the regular brain samples. 
The ice-cold centrifuge tubes were next centrifuged for 
15 minutes at 3800 X g •. Following centrifugation, the super-
natant was filtered using Watman #1 filter paper into a 15 
ml. graduated conical tube kept in an ice bath. After 30 
minutes, the volume of filtered extract was measured and 
recorded. The tubes were then sealed and placed overnight in 
a refrigerator. 
column preparation: 
The columns to be packeq with ion-exchange resin have been 
adapted from 1.0 ml. disposable syringes. It is necessary that 
the internal diameter of the syringe barrel be 4.2-4.5 mm •• 
The upper lip of the syringe was cut off and a 2 cm. piece 
of tygon tubing affixed to the top of the syringe barrel in 
such a way that one centimeter of tubing extended above the 
top of the barrel. This "column assembly" was then submerged 
in a beaker containing distilled water. It is necessary that 
the actual packing of the column with resin be done under air-
tight conditions, as air bubbles will disrupt the uniform 
• 
packing of the resin. Air bubbles were removed from the empty 
column by inserting a stirring rod inside the column and 
working it up and down a few times. With the column completely 
filled with water, a small ball of Pyrex glass wool was inserted 
into the column and forced to the tip with a stirring rod. 
This piece of glass wool serves to trap the resin within the 
48 
column. A two milliliter pipet is then filled with AG SOW 
X4 200-400 mesh H+ form ion-exchange resin which has been 
suspended in 0.01 M phosphate buffer plus 1 percent EDTA for 
at least 24 hours. The tip of the filled pipet was inserted 
under water into the tygon tubing attached to the top of the 
column. The resin was then allowed to flow into the column. 
After the resin bed has settled and a height of 50 mm. of 
resin attained, another ball of Pyrex glass wool was inserted 
into the top of the column, the resin bed now being contained 
between the two glass wool retainers. The freshly packed 
columns were then mounted onto the "column board". The 
"column board" consisted of a 20 ml. graduated glass syringe 
mounted firmly through a horizonal board which is secured to 
ring stands. A 3-way plastic stopcock was attached to the 
tip of this syringe. To the left of this syringe, a 20 ml. 
plastic syringe barrel was mounted in similar fashion as the 
glass syringe. This plastic syringe barrel served as a reser-
voir through which the extract and other reagents can be 
added to the column. The reservoir and glass syringe are 
connected through a series of ~lastic stopcocks in a way 
that liquids can be drawn into the glass syringe from the 
reservoir. On the open end of the stopcock attached to 
the glass syringe, a plastic fitting was placed. This fitting 
allows for an air-tight seal to be made between the tygon 
tubing on the column and the stopcock on the glass syringe. 
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This fitting was made by removing the metal insert of a 
disposable needle and using as the fitting, the upper plastic 
portion. 
Prior to attachment of the freshly packed resin column, 
distilled water was drawn through the stopcock into the glass 
syringe to remove any air from the stopcock. With the distilled 
water slowly dripping through the stopcock, the resin column 
was fitted tightly onto the stopcock fitting. The column 
was now mounted in such a way as to allow for liquids to be 
drawn into the glass syringe from the reservoir and then 
to flow through the resin column. The resin was next made 
ready for addition of the tissue extracts by cycling the resin 
from the H+ form to the Na+ form. The cycling was accomplished 
by passing 20 mls. of 0.01 M sodium phosphate buffer plus 
1 percent EDTA at pH 6.5 through the resin at a flow rate 
of one drop every 10 seconds. After the buffer has passed 
through the column the pH of the effluent was checked. A pH 
of 6.5 indicated that the column was cycled and ready to 
receive the tissue extract. 
Before adding the extract to the column, the pH was adjusted 
' 
to 6.5 using 5 N. potassium carbonate. A brom phenol blue pH 
indicator (pH 6.0) was added to the extract to speed up the 
titration, although final pH was determined using short range 
pH paper. At pH 6.5, potassium perchlorate precipitates out 
of the neutralized extract. Storing for 10 minutes in the 
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refrigerator increased the precipitation rate. Following the 
cooling, the extract was centrifuged at slow speed for 3 
minutes to allow the precipitate to settle. The extract was 
then poured into the reservoir on the "column board", care 
being taken not to allow the precipitate to enter the 
reservoir. The extract was drawn into the glass syringe and 
allowed to flow through the resin at a rate of one drop 
every 10 seconds. 
After the extract has passed through the column, the resin 
was washed with two 20 ml. volumes of distilled water. The 
flow rate for these two washed can proceed at a faster rate 
than the extract. 
Following the washes, the reservoirs were filled with 1 
N. hydrochloric acid. During the elution of the norepinephrine 
and dopamine fractions, the flow rate for the hydrochloric 
acid was maintained at one drop every 10 seconds. The first 
3 mls. of acid were passed through the column and. discarded. 
The next 8 and 13 mis. of acid eluted the norepinephrine and 
dopamine fractions, respectively. Following collection 
of the 8 ml. norepinephrine f~action the flasks were sealed 
and stored in the refrigerator. Flasks containing the dopamine 
fractions were treated similarly. 
Conversion of norepinephrine and dopamine to fluorophores: 
It was necessary to convert both norepinephrine and dopamine 
to their respective fluorophores before their respective 
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concentrations could be determined using a spectrophotofluorometer. 
separate conversion procedures were used for norepinephrine 
and dopamine, adding another degree of specificity to the 
method. The chemical conversion of norepinephrine to nor-
~pinephrinachrome to norepinephrinalutine (Bertler et al., 1958), 
the actual fluorophore, was carried out as follows. 
Distilled water 
0.01 M NaPO buffer 
4 
pH 6.5 
Neutralized eluate 
pH 6.5 · 
Std. RB _s_ IS TBf (mls.) 
3.80 3.90 2.90 2.80 2.90 
0.50 0.50 0.50 0.50 0.50 
---- ---- 1.00 1.00 1.00 
Standard NE (lµg/ml) 0.10 0.10 
0.5% Zinc sulfate 0.05 0.05 0.05 0.05 0.05 
0. 25% K Fe(CN) 0.05 0.05 0.05 0.05 0.05 
3 6 
5 minutes 
2 % ascorbic acid + 0.50 0.50 0.50 0.50 
SN. NaOH 
SN. NaOH 
---- ---- ---- 0.45 
• 
10 minutes 
2% ascorbic acid 
---- ---- ---- 0.05 
Upon completion of the above chemical procedure, the samples 
were poured into reading tubes and read in an AMINCO spectra-
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photofluorometer at 400/505 I11)l uncorrected excitation/emission 
wavelengths. The three tubes: sample (S), internal standard 
(IS), and tissue blank faded (TBf) comprised a set and were 
used for each sample eluate. Potassium ferricyanide was 
used as the oxidant in this conversion procedure because of 
its inability to convert dopamine to its respective fluoro-
phore. Such specificity added to the elimination of elution 
cross-over contamination, if any. The flurophore was found 
to be stable for up to one hour. 
Dopamine is similarly converted to dopaminachrome tq 
dopaminalutine, the actual fluorophore (Carlsson and Waldeck, 
1958). The conversion procedure for dopamine is as follows. 
Std. 
Distilled water 3.05 
Citrate-PO buffer0.50 
4 
pH 5.4 
Standard DA 0.25 
(lpg/ml) 
Unneutralized 
eluate 
Neutralized eluate----
pH 5.4 
Na SO - NaOH soln.----
2 3 
RB 
--
3.30 
0.50 
s IS TBu (mls.) 
--
1.30 1.05 1.30 
0.50 0.50 0.50 
0.25 
1.65 
' 
2.0 2.0 
0.50 
0.02 N. Iodine 0.10 0.10 0.10 0.10 0.10 (cont.) 
--..:......:....;~~_..;:;:~..;.._~~~~'--~~~~~~~~~~~~~~~-
Na SO - NaOH soln. 
2 3 
5 N. Acetic acid 
K CO SN• 
2 3 
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Std. IS 
--
5 minutes 
0.50 0.50 0.50 0.50 
5 minutes 
1.60 1.60 1.60 1.60 
TBu (mls.) 
1.60 
0.35 
Place in boiling water bath for 15 minutes 
After cooling the samples, they were poured into reading 
tubes and read in the fluorometer at 330/380 mp uncorrected 
excitation/emission wavelengths. Although the dopamine 
fluorophore is reported to be stable for 24 hours, all samples 
were read in the fluorometer within one hour. The boiling 
water bath is used to increase the intensity of the dopamine 
fluorophore in a shorter period than if it were left standing 
at room temperature. 
Due to inherent variation~ from sample to sample the rate 
of oxidation from one sample to the next varied when compared 
to the oxidation rate of the standard which does not contain 
tissue extract. Since the standard is used as the reference 
in determining the amount of amine present in each sample, 
it is critical that the rate of oxidation of the standard 
' 1 
~' 
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and each tissue sample are identical. Therefore, this method 
employs the use of an internal standard for the sole purpose 
of checking the sample rate of oxidation against that of the 
standard; the sample values were always corrected so that 
the standard and the sample had equal oxidation rates. 
The formula for calculating the pg/gm concentrations of the 
amines is as follows: 
1 / 2 / 3 1 4 = )lg/gm wet weight tissue. 
5 6 7 8 
1. Net (sample - blank) sample fluorometer units corrected for 
100% oxidation rate. 
2. Standard concentration (Jlg). 
3. Total eluate volume (ml) plus K CO volume (ml) used to 
2 3 
neutralize the eluate. 
4. Total volume of PCA (ml) used to homogenize tissue plus tissue 
water volume (ml) (75% of the tissue weight). 
5. Net fluorometer units of the reference standard. 
6. Volume (ml) of the eluate used in the sample. 
7. Volume of the extract (ml) recovered after filtration. 
8. Tissue weight (gm). 
' Additional reference may be found in the literature cited. 
Using the fluoromete~ values obtained from the tissue standard 
samples prepared with the brain samples, the percent recovery 
of both norepinephrine and dopamine can be calculated. 
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~ 
f' Jwerage recoveries for norepinephrine were found to vary 
between 70-80 percent, and those for dopamine between 50-
60 percent. These recoveries are consistent with those 
reported in the literature for this method. Brain sample 
pg/gm concentrations were always corrected for 100 percent 
recovery based on the standard recoveries obtained with each 
series of brain samples. 
rntraventricular studies: 
The first series of intraventricular injections of DFP 
were performed on rabbits who had been anesthesized with 
pentobarbital (30mg/kg, iv). The second series of intra-
ventricular injections of DFP were performed on unanesthesized 
rabbits, which were given 0.50 mls. of lidocaine (2.0mg/ml) 
locally into the scalp. With the exception of the anesthesia, 
both groups of rabbits were treated identically. With the 
animals held in place by hand, the hair was clipped from the 
top of the head. In the case of the second group of rabbits, 
lidocaine was now injected into the scalp. A longitudinal 
incision was made down the cen.J:.er of the scalp. Using a 
scalpel blade, the skull was cleared of muscle and connective 
tissue on the left side of the midline suture near the 
coronal suture. Following removal of the surface tissue, bone 
wax was applied to the skull to stop any bleeding from the 
bone itself. Next, using predetermined coordinates, a point 
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• r was found which was 4.0 mm. caudal to the coronal suture and 
~ 
~ F 4 .5 mm. lateral to the midline suture. At this point a small ~ . 
hole was drilled using an electric Dremel Moto drill containing 
a 1/32 inch drill bit. Care was made to penetrate only the 
bone. Bone wax was then applied to the opening. The rabbits 
were replaced in their cages for a one hour period; allowing 
them to settle down before beginning the drug regime. The 
actual surgical treatment did not produce any observable 
signs of stress; the unanesthesized and the anesthesized 
rabbits showed similar behavior following the recovery of 
the latter from anesthesia. 
After one hour had elapsed, the rabbits were given the first 
in a series of drug treatments. There were three drug 
combinations used: JB835-DOPA-Saline; JB835-DOPA-DFP; and 
JB835-DOPA-ATMN-DFP. The doses for JB835, DOPA, and ATMN, 
as well as the administration sequences for all drugs 
including DFP were described earlier. The dose of DFP used 
in these studies was 200pg contained in a constant volume 
of 100)11. The preparation of the DFP and saline used in 
these experiments was describE\(l earlier. A lOOµg dose of 
DFP in a 100µ1 volume were previously used by Feldberg (1958) 
in intraventricular injections. In preliminary trials it 
was found in these laboratories that the rabbits tolerated lOOpg and 
200pg of DFP equally well via the intraventricular route, 
IC f1 
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dose volume being constant. It was decided on this basis 
L'· and on that of preliminary neurochemical findings that 200)lg' 
f .. ,. 
of DFP in a dose volume of lOOpl would be used in the actual 
experiments. In the case of the sham operated control rabbits 
receiving JB835-DOPA-Saline, the volume of lOOpl was injected 
intraventricularly. 
At the proper time in the administration cycle the intra-
ventricular injection of either DFP or saline was carried out, 
the rabbit again held securely in place. Using a 250pl glass 
syringe and a 27 gauge stainless steel needle, which had been 
prepared to a length of 6.0mm., the 100µ1 volume was loaded 
into the syringe. Maintaining a vertical plane to the skull, 
the needle was lowered through the wax-filled hole. As soon 
as the needle was fully inserted (up. to the flared portion of 
the needle acting as a stop) the dose volume was slowly injected 
into the lateral ventricle, the needle withdrawn, and the 
hole immediately refilled with bone wax. The animals were 
then replaced in their cages for one hour and sacrificed. 
Preliminary trials using various coordinates and injection 
depths were performed to insufe that the described procedure 
did place the dose volume within the left lateral ventricle. 
Using Brom Phenol Blue, which stains the tissues it comes in 
contact with, 100-SOOpl volumes were injected and the brains 
removed and dissected, the location of the staining was then 
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determined. The 4.0mm. X 4.5mm. coordinates were found to 
place the needle tip within the desired left lateral ventricle 
as indicated by the complete staining of the walls of the left 
lateral ventricle, as well as of the walls of the aqueduct and third 
ventricle walls using the 100µ1 volume of the dye. The 500µ1 
dye volume stained the walls of all ventricles and the 
aqueducts associated with them. Repeated trials were performed 
and each time the dye was observed only on the walls of the 
ventricular system. Other coordinates do appear in the 
literature for intraventricular injections. A variety of 
coordinates could be used since the left lateral ventricle 
runs parallel to the midline suture; however, in these studies 
the 4.0mm. X 4.5mm. coordinates were found preferable. As 
an additional precaution, while dissecting the brain parts 
out, visual location of the entry point of the needle was eval-
uated to verify entry into the ventricle, the surrounding 
tissues were inspected as well to be sure that the needle 
did not enter one of these tissues. Injection into the left 
lateral ventricle was visually confirmed in all animals receiving 
an intraventricular injection.' 
Some comment should be made regarding the symptomatology 
of the rabbits following intraventricular injection of DFP, 
Due to the pretreatment of JB835-DOPA, the animals exhibited 
piloerection, hyperreflexia, and mydriasis. Following intra-
ventricular administration of DFP, the animals began to exhibit 
' . 
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intermittent seizures beginning after about 5 minutes. These 
seizures consisted of leg jerking, rolling over, and spinning 
in a clockwise or counterclockwise direction which varied 
from rabbit to rabbit. This seizure period lasted for from 
5-10 minutes after which the rabbits assumed a fixed position; 
some animals rocked back and forth while in this position. 
During the remaining time the rabbits exhibited a chewing jaw 
motion; one actually bit its tongue enough to cause bleeding. 
In addition, the rabbits seemed to have a lowered threshhold to 
audiogenic seizures; a loud sound caused sudden short bursts 
of leg jerking. Most of the rabbits salivated during the 
latter half of the post-drug period. DFP did not produce 
miosis in any of the animals when given via this route. 
Piloerection disappeared and the hair remained flat. Skeletal 
muscle fasciculations were not observed. Feldberg (1958) 
reported similar behavorial symptoms in cats given DFP intra-
ventricularly. 
These symptoms differed in many respects to those seen 
following DFP via the subcutaneous route. When DFP was given 
subcutaneously, miosis always fCCurred (except when atropine 
treatment was employed), there was no apparent change in 
audiogenic seizure threshhold, skeletal muscle fasciculations 
were observed, the rabbits did not assume a fixed position, 
did not rock back and forth or spin in either clockwise or 
counterclockwise direction. Sham-operated control rabbits 
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receiving 100µ1 of saline at pH 3.61 did not exhibit any of 
the symptoms seen following DFP in either anesthesized or 
unanesthesized rabbits; in fact their behavior was identical 
to that of rabbits receiving JB835-DOPA, but not treated 
surgically •. 
fholinesterase activity assay: 
Cholinesterase activity was measured in control rabbits 
(no drugs), in rabbits treated with JB835-DOPA; JB835-DOPA-
DFP; and JB835-DOPA-AtSO -DFP combinations. The doses and 
4 
drug administration sequences were already described. Cholin-
esterase activity was measured in midbrain, thalamus, hypo-
thalamus, and caudate nucleus; two separate samples of each 
part were used in each drug group. The method used for 
measurement of the cholinesterase activity was previously 
described by Ellman et al. (1961). The procedure was as 
follows. The animals were pretreated with the above mentioned 
drug combinations or given no drugs in the case of the control 
rabbits; they were sacrificed and the brain areas removed as 
described earlier. After weighing the individual brain parts, 
' they were homogenized in ice-cold 0.10 M phosphate buffer, 
pH 8.0. All tissues were homogenized to a final weight/volume 
concentration of 20mg/ml •• The 20mg/ml. homogenates were kept 
in an ice bath until ready for the cholinesterase assay. 
In pretrial experiments it was found that the 400pl homo-
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genate volume described by Ellman et al. was not satisfactory 
for the control rabbit assays, as the cholinesterase activity 
in control rabbit brain parts was too high for an accurate 
measurement when the 400µ1 volume was used. 200µl's of 
homogenate was found to be acceptable and was used in these 
• 
assays. To control for color formation due to other than 
cholinesterase materials, an eserinized blank was run with 
the tissue sample, both containing the same volume of homo-
-5 
genate. The 3 X 10 M dose of eserine was reported to 
inhibit 100 percent of the acetylcholinesterase activity while 
only inhibiting 25 percent of the butrylcholinesterase activity, 
thus after subtraction of the blank activity from the sample 
activity, the cholinesterase activity remaining would represent 
primarily only that due to acetylcholinesterase. During 
each enzymatic assay, a DFP-treated brain part and its respective 
blank were run together with an identical non-DFP treated 
brain part. Thus, not all DFP brain samples were run together, 
a system that could induce error. Over the course of the 
enzymatic study, brain parts from animals treated with JB835-
DOPA-DFP and JB835-DOPA-AtSO -~FP drug combinations were run 
4 
against identical brain parts from both control (no drug) 
animals, as well as JB835-DOPA treated animals. 
The sequence of events for each enzymatic measurement were 
as follows. The Beckman DU spectrophotometer absorbancy wave-
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length was set for 412 mµ as described by Ellman et al •• After 
an adequate warm up period (1 hour), the sensitivity and 
dark current was adjusted such that the null indicator read 
zero. A standard quartz photocell containing 0.10 M phosphate 
buffer pH 8.0 was used to make these adjustments. Next, 
the photocells were removed and 200pl of homogenate was added 
to the sample and to blank photocells. To the blank photocell 
lOOpl of eserine was added producing a final volume concentration 
. -5 
of 3 X 10 M, which inhibited all of the acetylcholinesterase 
activity and 25 percent of the butrylcholinesterase activity. 
To each photocell 100µ1 of DTNB (Di-thio-bis nitrobenzoic acid) 
was added and the reagents in the cell mixed by blowing air 
bubbles through the cell. The photocells were replaced in 
the cell housing of the photometer. The increasing absorbance, 
owing to DTNB's reaction with non-specific cholinesterases, i.e. 
thiolesterases, and protein, was monitered until a peak absorb-
ance was reached. Using the slit adjustment knob, the null 
needle was returned to zero. The photocells were again 
removed from the cell-housing and 200µ1 of acetylthiocholine 
substrate was added to each cell and mixed with air bubbles. 
' 
A 10 second interval was maintained between the cell sequence 
so that a proper timing sequence could be maintained during 
subsequent absorbancy measurements. The photocells were 
quickly replaced in the photometer and absorbancy measurements 
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of each cell made at 1, 2, 4, and 6 minute intervals. When 
all samples had been run for that day (3 hours after the first 
measurement), the first sample was rerun to check for loss 
of enzyme activity. No loss of enzyme activity was observed 
over the testing period. 
It was found that the caudate nucleus tissue samples from 
control and JB835-DOPA treated rabbits had, at six minutes, 
surpassed the maximum absorbancy measurable. To stay within 
the linear portion of the absorbancy curve, the four minute 
absorbancy value, minus the respective blank value, was 
used to calculate the mean change in absorbance/minute for all 
samples. From this value the average change in absorbance/ 
minute was determined for each pair of brain parts within 
each drug group. 
The JB835-DOPA treated rabbits served as the sham control 
' group and the mean acetylcholinesterase activity for each 
part within this group was considered to represent 100 percent 
cholinesterase activity with respect to the two DFP treated 
groups. The rate of hydrolysis (moles of substrate hydrolyzed/ 
minute/gram of tissue) of acei:Jylcholinesterase was calculated 
using the formula described by Ellman et al. (1961). 
Acetylcholine bioassay; 
Acetylcholine levels of rabbit brain thalamus, hypothalamus, 
midbrain, and caudate nucleus were measured using bioassay 
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techniques on guinea pig ileum. Animals were pretreated with. 
JB835-DOPA; JB835-DOPA-DFP; JB835-DOPA-AtSO -DFP; JB835-DOPA-
4 
ATMN-DFP drug combinations; control animals (no drugs) were 
also used. The doses and administration sequences have been 
described earlier. The bioassay procedures used were based 
on methods described by Magnus (1904); Turner (1965); and 
Livingston (1968) with modifications by Kindel (1971). 
Following drug pretreatment, the animals were sacrificed and 
the brain parts were removed as described earlier. Once 
removed the individual brain parts were quick-frozen in liquid 
nitrogen. To prechilled homogenizing vessels, 4 mls. of 
eserinized (20pg/ml) bicarbonate-free Locke Ringer solution 
with 1/15 M sodium phosphate monobasic buffer pH 6.68-7.30 
are added. The ratio of bicarbonate-free Locke Ringer and 
1/15 M sodium phosphate monobasic buffer was 3.333/1.000. 
To the 4 mls. of buffer solution, 0.5 mls. of 0.333 N. hydro-
chloric acid was added and the two solutions mixed. The first 
brain part was removed from the liquid nitrogen, weighed, and 
placed into the homogenizing vessel. The tissue was homogenized 
using a power driven pestle for 2-3 minutes keeping the homo-
' genizing tube in an ice bath during the entire procedure. 
After homogenization, the homogenate was placed in a boiling 
water bath for 10 minutes. Upon removing the vessel from 
the water bath, the homogenate was mixed using a Vortex mixer 
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50 that any tissue residue on the upper walls of the vessel 
was mixed in with the homogenate. The homogenate was then 
allowed to cool. Once cooled, the homogenate was poured into 
a thick-walled centrifuge tube. 1.0 ml. of cold distilled 
water was then added to the homogenizing vessel as a wash. 
After swirling in the vessel, the wash was added to the 
homogenate in the centrifuge tube. The homogenate was then 
centrifuged for 15 minutes at 3800 X g •• Following centrifug-
ation, the supernatant was poured into another centrifuge 
tube and the tissue pellet re-extracted with 1.0 ml. of the 
bicarbonate-free Locke Ringer solution without eserine. ~he 
re-extracted homogenate was centrifuged for 15 minutes at 
3800 X g •• The supernatants from both the first extraction 
and the re-extraction were pooled and neutralized to pH 6.8-
7.0 with 0.333 N. sodium hydroxide. The neutralized extract 
was then centrifuged at 3800 X g •• The supernatant was poured 
into a centrifuge tube containing alpha chymotrypsin (400pg/ml 
of extract). The extract and chymotrypsin were mixed, the 
centrifuge tube stoppered, and the extract incubated for 10 
minutes at 38 degrees Centigrade in a dry incubator. After 
' 
the incubation, the volume of the extract was measured and 
recorded. 2.5 mls. of the extract was removed and added to 
another centrifuge tube to be used later with acetyicholine 
standard. The sample extract was then stoppered and frozen 
66 
until bioassayed. 
0.40 mls. of 0.333 N. sodium hydroxide was then added to 
the 2.5 mls. of extract isolated for use with acetylcholine. 
The two solutions were mixed and the extract incubated in a 
boiling water bath for 10 minutes. This procedure destroys 
any acetylcholine present. After boiling, the extract was 
cooled and centrifuged for 15 minutes at 3800 X g •• The 
supernatant was poured into a centrifuge tube and neutralized 
with 0.333 N. hydrochloric acid to pH 6.8-7.0. The neutralized 
extract was stoppered and frozen for later use. 
Simply stated, the extraction steps include: (1) homogenization 
of the tissue and acid extraction of the acetylcholine. (2) 
heating of the homogenate to destroy all cholinesterase present 
in the tissue. (3) centrifugation and re-extraction of the 
tissue pellet. (4) neutralization of the extract. (5) addition 
of chymotrypsin to the extract which destroys substance 11 P 11 , 
aided by incubation. (6) bioassay of the acetylcholine present 
in the tissue extract on guinea pig ileum. 
Bioassay: 
' Tyrode solution was prepared with lpg/ml. of morphine, 
0.2pg/ml. of pyrilamine, and 0.03µg/ml. of dibenzyline. Morphine 
was used to decrease spontaneous activity of the ileum: 
pyrilamine and dibenzyline blocked any histamine and serotonin, 
respectively, still present in the extract. 
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The guinea pig was sacrificed by a blow on the head. The-
ileum was isolated, removed, and flushed with Tyrode solution. 
A piece of the ileum was then mounted in the 5 ml. organ bath 
aerated with 5 percent CO 
2 
and 95 percent o . 
2 
A lOOµg dose 
of acetylcholine was used to test the sensitivity of the 
preparation. If sensitive, the preparation was allowed to 
stand for one hour to allow its accomodation to the bath. 
Using acetylcholine, a dose producing a maximal response 
of the ileum was found as well as a dose producing 75 percent 
of maximal response. Repeated doses of the latter dose were 
given to assure a constant response. Using the tissue extract, 
which has been allowed to thaw, the volumes necessary to induce 
a high and low effect were found; the high "dose" was capable 
of double the response seen with the low "dose". With these 
two extract responses established, doses of authentic acetyl-
choline were found which mimicked the two responses produced 
by the tissue extract. These two doses of authentic acetyl-
choline were used repeatedly to assure constant ileum responses. 
An amount of acetylcholine is then added to the 2.5 mls. of 
extract which had been put aside for the acetylcholine 
' 
standard, the high and low "dose" volumes from this standard-
extract preparation capable of inducing approximately the 
high and low "dose" (volume} responses produced by the tissue 
extract we've selected. After establishing that the responses 
to the acetylcholine-extract standard and the tissue extract 
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were constant, a latin square was completed. From the latin 
square data, acetylcholine levels in the various brain parts 
were calculated and expressed as pg/gm (Livingston, 1968). 
Upon completion of the latin square, serotonin and histamine 
were added to the bath to assure that responses to both were, 
still blocked by the blocking agents added to the Tyrode 
solution. 
statistics: 
The statistical analysis of the data presented in this 
dissertation was carried out by means of the unpaired Student 
"t" test, the samplings corning from two groups of rabbits. 
The degrees of freedom used in the establishment of the 
probability (P) values were n-1 for each group with the 
total degrees of freedom being n-2. Statistical significance 
of the data was accepted when the "P" value was 0.05 or less. 
In some cases where the sample size was small and there was a 
drug-induced shift in the mean value, "P" values of 0.10-
0.05 were shown. Although this value does not indicate 
statistical significance as per standards established for 
' statistical analysis, it was felt that a clear trend was 
indicated in the case of the data in question; had large 
sample sizes been used, statistical significance would have been 
proven. 
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RESULTS 
The effects of JB835 and DOPA on norepinephrine and dopamine 
-
1evels. 
-
As expected, it was found that either JB835 or DOPA increased 
the levels of norepinephrine over their control concentrations 
in both caudate nucleus and in the midbrain-diencephalon; the 
dopamine levels were increased at least in the case of the 
former (Table I). In the case of the caudate nucleus, JB835 
increased the levels of norepinephrine and dopamine by 52 
and 19 percent respectively. Similar increases in norepinephrine 
occurred in the case of the midbrain-diencephalon, JB835 
inducing a 52 percent increase and DOPA- a 16 percent increase. 
However, the concentration of midbrain-diencephalon dopamine 
was not increased above control levels by either JB835 or 
DOPA (Table II). 
Furthermore, DOPA-JB835 combinations induced even more 
pronounced increases in the levels of norepinephrine in both 
the caudate nucleus and in the midbrain-diencephalon area 
• 
(by 55 and 270 percent, respectively). Also, this dose 
combination induced an increase of dopamine levels in the case 
of the caudate nucleus which was significantly greater than 
that induced by JB835 or DOPA alone (Table I; Fig_ure I). 
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Moreover, while neither the monoamine inhibitor nor DOPA, 
employed alone, increased the level of dopamine in the case 
of the midbrain-diencephalon, their combination induced a 
significant increase of dopamine in this area (Table II: Figure 
2) • 
The effect of DFP on norepinephrine and on the dopamine levels 
in otherwise non-treated and pretreated animals. 
With this background of information, DFP was employed at 
two dose levels, 1.0 and 2.5 mg/kg, in rabbits otherwise not 
treated, or pretreated with the DOPA-JB835 combination. It 
was of interest that DFP affected significantly dopamine 
and norepinephrine levels only in pretreated animals, i.e. /-
•' in the rabbi ts which were "loaded", following the appropriate 
pharmacological maneuvers, with the catecholamines. 
In animals which were not pretreated with DOPA and/or the 
monoamine oxidase inhibitor, neither dose of DFP induced a 
significant change in norepinephrine and dopamine, whether 
in the case of the caudate nucleus or of the mid.brain-
diencephalon region (Figures 3 and 4). Slight increases in 
norepinephrine were recorded with both doses of DFP in the 
case of the midbrain-diencephalon, and with the larger 
dose of DFP in that of the caudate nucleus; a relatively 
large but statistically not significant decrease in norepinephrine 
was found following 1.0 mg/kg dose of DFP in the case of the 
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TABLE I 
Effects of DFP in the Caudate Nucleus on Norepinephrine (NE) 
and Dopamine (DA) Levels. 
Drug* Mean NE ± S.E. No.** Mean DA + - S.E. No. 
DOPA 0.438 ;!; 0.032 4 8.913 ;!; 1.339 6 
DOPA + DFP 0.322 ;!; 0.083 6 6.841 ;!; 0.938 6 
JB835 0.498 ~ 0.117 4 7.162 ± 0.762 4 
JB835 + DFP 0.238 ± 0.016 4 5.904 ± 0.497 5 
JB835 + DOPA 0.592 ± 0.054 8 8.306 ± 0.568 10 
JB835 + DOPA + DFP 0.221 ± 0.028 9 9.110 ± 0.809 10 
Control 0.328 ± 0.069 8 6.004 ± 0.579 15 
* JB835, 6 mg/kg (ip}; DOPA, 50 mg/kg (ip}; DFP, 2.5 mg/kg (sc). 
The controls were given saline. 
** S.E. = standard error; No. = number of individual determinations. 
' 
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TABLE II 
Effects of DFP in the Midbrain-Diencephalon on Norepinephrine (NE} 
and Dopamine (DA} Levels. 
Drug_ Mean NE + - S.E. No. Mean DA ± S.E. No. 
DOPA 0.393 ± 0.035 6 0.225 ± 0.047 4 
DOPA + DFP 0.226 ± 0.033 6 0.199 ± 0.053 6 
JB835 0.513 ± 0.100 4 0.142 ± 0.024 4 
JB835 + DFP 0.243 ± 0.084 6 0.394 ± 0.107 5 
JB835 + DOPA 0.910 ± 0.141 8 0.377 ± 0.073 8 
JB835 + DOPA + DFP 0.362 ± 0.055 11 0.875 ± 0.151 10 
Control 0.336 ± 0.035 19 0.257 ± 0.045 11 
For other explanations, cf. Table I • 
.• 
.-. 
" 
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LEGEND FOR FIGURE I 
Effect of JB835 (6 mg/kg, ip) and DOPA (50 mg/kg, ip), with 
or without DFP (2.5 mg/kg,sc); and DFP alone (2.5 mg/kg,sc} 
on caudate nucleus norepinephrine and dopamine levels. 
control values are indicated with the horizontal line. Values 
are expressed as the Mean + the standard error and represent 
4-10 individual determinations. The level of significance 
was calculated using Student's test. 
o indicates P(0.001 for the difference between bargraphs 
2 and 3. 
• 
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LEGEND FOR FIGURE 2 
Effect of JB835 (6 mg/kg, ip) and DOPA (50 mg/kg, ip), 
with or without DFP (2.5 mg/kg,sc); and DFP alone (2.5 mg/kg, 
sc) on midbrain-diencephalon norepinephrin~ and<bpamine 
levels. Control values are indicated by the horizontal line. 
Values are expressed as the Mean + the standard error and 
represent 4-10 individual determinations. The level of 
significance was calculated using Student's test. 
+ indicates P(0.005 and • indicates P(0.025 for the difference 
between bargraphs 2 and 3 in the upper and lower horizontal 
rows, respectively. 
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LEGEND FOR FIGURE 3 
Effect of DFP (1.0 and 2.5 mg/kg, sc); and JB835 (6 mg/kg, 
ip) plus DOPA (50 mg/kg, ip), with and without DFP (1.0 and 
2.5 mg/kg, sc) on caudate nucleus norepinephrine and dopamine 
levels. Values are expressed as the Mean + the standard 
error and represent 4-10 individual determinations. Control 
levels (not shown) are 0.328 + 0.069 and 6.004 + 0.579 for 
norepinephrine and dopamine respectively. Significance was 
calculated using Student's test. 
•indicates P<0.005 for the difference between bargraphs 
3 and 4; o indicates P<0.001 for the difference between 
bargraphs 3 and 5. 
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LEGEND FOR FIGURE 4 
Effect of DFP {1.0 and 2.5 mg/kg, sc); and JB835 (6 mg/kg, 
ip) plus DOPA {SO mg/kg, ip), with and without DFP {1.0 and 
2.5 mg/kg, sc) on midbrain-diencephalon norepinephrine and 
dopamine levels. Values are expressed as the Mean + the 
standard error and represent 4-10 individual determinations. 
Control levels {not shown) are 0.336 + 0.035 and 0.257 + 
0.045 for norepinephrine and dopamine respectively. 
Significance was calculated using Student's test. 
• indicates P(0.025 for the difference between upper bargraphs 
3 and 4, and also lower bargraphs 3 and 5. o indicates P~ 
0.005 for the difference between upper bargraphs 3 and 5. 
' 
r 81 
~ 
"; 
~. iatter. The changes in dopamine levels induced by DFP 
whether in the case of the midbrain-diencephalon area or 
· of the caudate nucleus were even less marked than those in 
norepinephrine concentrations (Figures 3 and 4) • 
To the contrary, in "loaded" animals, i.e. in the animals 
in which the levels of norepinephrine and of dopamine were 
increased by the pretreatment, DFP (2.5 mg/kg) produced a 
significant change with respect to the "loaded" state in both 
the monoamines in the case of the caudate nucleus as well as 
in that of the midbrain-diencephalon region when employed at 
the larger dose; the smaller dose of DFP exerted less of an 
effect, although the trend of the data was similar with both 
doses of the anticholinesterases. 
Perhaps surprisingly, the general direction of the changes 
was toward increased levels of dopamine and decreased levels 
of norepinephrine. These changes were generally more pro-
nounced in the case of the midbrain-diencephalon area than 
in that of the caudate nucleus; moreover, the magnitude of 
the change induced by DFP relative to the "loaded" state was 
generally greater in the case ~f the animals pretreated by 
JB835 than in that of the animals pretreated by DOPA (Figures 
5 and 6), while the maximal change due to DFP was found in 
the case of animals pretreated with the JB835-DOPA combination 
(Figures 1 and 2). It should be noted that this was also 
the order of the increase in norepinephrine or dopamine levels 
induced by DOPA, JB835, and JB835-DOPA combination (Table II, 
r- 82 
~ ,, 
Figures 2 and 6). 
Specifically, the results in question were as follows 
(the percent change in monoamines induced by DFP after 
DOPA, JB835, or JB835-DOPA treatment represent the change 
relative to the monoamine levels in similarly pretreated 
animals that were not given DFP): In the case of .the 
~idbrain-diencephalon area, DFP, at 2.5 mgjkg, induced a 53 
percent decrease in norepinephrine level in the animals 
pretreated by JB835, while 43 percent decrease in norepinephrine 
was noted following the pretreatment with DOPA.· In the case 
of the animals pretreated with DOPA and JB835 a 60 percent 
decrease was noted following 2.5 mg/kg DFP. Somewhat less 
consistent data were obtained with regard to dopamine, although 
generally an increase in this monoamine was noted. A small 
(12 percent) decrease was noted after DFP (2.5 mg/kg) in 
the case of the DOPA-pretreated rabbits, while a very marked 
increase in dopamine occurred in the case of the animals 
pretreated with JB835 or with the JB835-DOPA combination: a 
177 percent increase was found in the former case following 
the 2.5 mg/kg dose of DFP, an<\ a 135 percent increase was 
recorded with the 2.5 mg/kg dose of DFP following the JB835-
DOPA pretreatment. It should be noted that in this case the 
change following the JB835-DOPA pretreatment was somewhat 
smaller than that following pretreatment with JB835 alone. 
However, the increase in dopamine levels of the mid.brain-
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LEGEND FOR FIGURE 5 
Effect of JB835 (6 mg/kg, ip); and DOPA (50 mg/kg, ip), 
with or without DFP (2.5 mg/kg, sc) on caudate nucleus 
norepinephrine and dopamine levels. Values are expressed as 
the Mean + the standard error and represent 4-6 individual 
determinations. Control values (not shown) are 0.328 + 0.069 
and 6.004 + 0.579 for norepinephrine and dopamine respectively. 
The level of significance was calculated using Student's 
test. 
•indicates P(0.10-0.05 for the difference between bargraphs 
3 and 4. 
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LEGEND FOR FIGURE 6 
Effect of JB835 (6 mg/kg, ip); and DOPA (50 mg/kg, ip), 
with or without DFP (2.5 mg/kg, sc) on midbrain-diencephalon 
norepinephrine and dopamine levels. Values are expressed 
as the Mean + standard error and represent 4-6 individual 
determinations. Control values (not shown) are 0.336 + 0.035 
and 0.257 ± 0.045 for norepinephrine and dopamine respectively. 
The level of significance was calculated using Student's 
test. 
o indicates P<0.01 for the difference between bargraphs 
1 and 2; & indicates P(0.10-0.05 for the difference between 
bargraphs 3 and 4 in both the upper and lower horizontal rows • 
• 
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i· diencephalon area in the "loaded" state of the animal was 
very pronounced; it coresponded to almost a two-fold change 
compared to the controls and it was much more marked than that 
recorded in the "loaded" animals in the case of the caudate 
nucleus (Table 1). In this situation, DFP may have saturated 
the capacity of the midbrain-diencephalon area as it elevated 
thecbpamine levels to 0.875 microgm./gm. compared to the 
0.257 microgm./gm. level of the controls (Table 2). 
In the case of caudate nucleus, DFP induced, similarly, 
marked decreases in norepinephrine in pretreated rabbits. A 
26 and a 52 percent decrease were found with the 2.5 mg/kg 
dose of DFP in animals pretreated with DOPA and JB835, 
respectively; an even greater change occurred in animals 
pretreated with a JB835-DOPA combination, as the decrease 
with this dose of DFP amounted to 63 percent; a 13 percent 
decrease was noted following the smaller dose of 1.0 mg/kg. 
The DFP-induced changes in dopamine levels of the caudate 
nucleus were less consistent than those in the norepinephrine 
levels. DFP (2.5 mg/kg) induced relatively small decreases 
"~·. · .. 
in dopamine level following ei~her DOPA (23 percent) or JB835 
(18 percent); however, under maximal loading conditions, 
i.e~ after JB835-DOPA pretreatment, a small increase (9 percent) 
in the levels of dopamine was noticed (Table l); none of these 
changes were statistically significant. 
r 88 ~ f !!l-e effects of atropine and atropine methyl nitrate. 
,, 
It may be expected that the effects of DFP on dopamine and/ 
or norepinephrine were due to accumulated acetylcholine; in 
fact, results indicating the occurrence of such an accumulation 
'have been obtained (cf. below section "acetylcholine levels"). 
It may be then further surmised that atropine should block 
the effects of DFP on the monoamines, while the quaternary 
atropine, atropine methyl nitrate, which does not readily 
penetrate into the brain, should be less effective in this 
respect. Pertinent experiments were therefore carried out 
under maximal "loading" conditions, i.e. following the pre-
treatment with JB835-DOPA combination. 
The results were not always as expected. The DFP-
induced decrease in the norepinephrine levels of either the 
caudate nucleus or of the midbrain-diencephalon area was partially 
blocked by 48 and 64 percent, respectively with atropine, 
2.0 mg/kg, given i.p. prior to DFP (Figures 7 and 8). 
Similarly, atropine prevented, at the same dose, most of the 
increase in dopamine due to DFP in the case of the midbrain-
diencephalon level (Figure 8). However, the effect of DFP 
" 
on the dopamine levels' of the caudate nucleus was not effected 
by atropine (Figure 7). It should be pointed out however 
that, in the case of the caudate nucleus, the effect of DFP 
on the levels of dopamine following pretreatment with JB835-
· DOPA combinations was statistically not significant (cf. above, 
1.00 
Q80 
0.60 
0.40 
Q20 
!::• 0.00 11 ~~ 
~1:" 
10.00 if b·~ 
~~f\< 
f: 
8.00 
6.00 
4.00 
2.00 
0.00 
J.\O/om 
89 
CAUDATE NUCLEUS 
~ 
0 
0 
s 
+ 
~ 
CD 
.., 
• 
0 
' 
NOREPINEPHRINE 
DOPAMINE 
la.I 
+1- •=<0.05 ~c( 0~ 0 (0.001 o=>a. 
.JCl>I&.. 
Owo 
+z+ 
It> Ii: ~o 
ma:: 
..,ti 
---· -·---·----------------·-----
FIGURE 7 
90 
LEGEND FOR FIGURE 7 
I 
Effect of JB835 (6 mg/kg, ip) and DOPA (SO mg/kg, ip), 
with and without DFP (2.5 mg/kg,sc) or atropine sulfate 
(2.0 mg/kg, ip) and DFP (2.5 mg/kg, sc) on caudate nucleus 
norepinephrine and dopamine levels. Values are expressed 
as the Mean + the standard error and represent 4-10 individual 
determinations. Control values are indicated by the horizontal 
line. Significance was calculated using Student's test. 
o indicates P<0.001 for the difference between bargraphs 1 
and 2; • indicates P(0.05 for the difference between bargraphs 
2 and 3. 
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LEGEND FOR FIGURE 8 
I 
Effect of JB835 (6 mg/kg, ip) and DOPA (50 mg/kg, ip), 
with and without DFP (2.5 mg/kg, sc) or Atropine sulfate (2.0 
mg/kg, ip) and DFP (2.5 mg/kg, sc) on midbrain-diencephalon 
norepinephrine and dopamine levels. Values are expressed as 
the Mean + the standard error and represent 4-10 individual 
determinations. Control values are indicated by the horizontal 
line. Significance was calculated using Student's test. 
• indicates P<0.01 for the difference between bargraphs 2 and 
3. The bargraphs 1 and 2 in both horizontal rows also differed 
significantly(cf. Figure 1). 
' 
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Figure 1). 
Even more surprising were the results obtained with atropine 
methyl nitrate (2.0 mg/kg), given i.p. prior to DFP, to 
rabbits under maximal "loading" conditions. While the 
quaternary atropine did not, as expected, block significantly 
the DFP effect on the levels of norepinephrine and of dopamine 
in the case of the caudate nucleus (figure 9), and while 
similarly it did not prevent the DFP-induced decrease of the 
level of norepinephrine in that of the midbrain-diencephalon 
·region, most unexpectedly it afforded complete protection 
against DFP-induced, otherwise marked increase in the midbrain-
diencephalon dopamine (Figure 10) • In fact, while both · 
atropine and quaternary atropine exhibited a similar blocking 
action upon the DFP-induced increase of dopamine in the midbrain-
diencephalon region, the effect of the latter was much more 
pronounced. 
It should be finally added that methylatropine (cf. Figures 
9 and 10) given alone (without DFP) to rabbits did not have 
any significant affect on the levels of either monoamines. 
' Time characteristics of the effect of DFP on norepinephrine 
and on dopamine. 
A possible explanation regarding the DFP-induced decrease 
in norepinephrine and elevation of dopamine observed in 
. animals pretreated with JB835-DOPA combinations (Figures 1 and 
2) could be the inhibition of dopamine-,4-hydroxylase, the 
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LEGEND FOR FIGURE 9 I 
Effect of atropine methyl nitrate (2.0 mg/kg, ip); and 
JB835 (6 mg/kg, ip) plus DOPA (SO mg/kg, ip), with or without 
DFP (2.5 mg/kg, sc) or atropine methyl nitrate (2.0 mg/kg, ip); 
and DFP (2.5 mg/kg, sc) on caudate nucleus norepinephrine 
and dopamine levels. Values are expressed as the Mean + the 
standard error and represent 4-10 individual determinations. 
Control levels are indicated by the horizontal line. Statistical. 
significance was calculated using Student's test. 
o indicates P<0.001 for the difference between bargraphs 1 
and 2. 
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LEGEND FOR FIGURE 10 
I 
Effect of atropine methyl nitrate (2.0 mg/kg, ip); and 
.JB835 (6 mg/kg, ip) plus DOPA (50 mg/kg, ip), with or without 
DFP (2.5 mg/kg, sc) or atropine methyl nitrate (2.0 mg/kg, ip}; 
and DFP (2.5 mg/kg, sc) on midbrain-diencephalon norepinephrine 
and dopamine levels. Values are expressed as the Mean + the 
standard error and represent 4-10 individual determinations. 
Control levels are indicated by the horizontal line. Signifi-
cance was calculated using Student's test. 
• indicates P(0.05 for the difference between bargraphs 2 and 
3. Bargraphs 1 and 2 in both horizontal rows also differed 
significantly (cf. Figure 1). 
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enzyme responsible for the conversion of dopamine to norepinephrine 
within the storage granules (Weiner, 1970). By inhibiting 
r this enzyme, DFP would allow dopamine levels to increase 1· 
~· 
~· t f ): 
while norepinephrine levels, after norepinephrine was released 
following the DFP treatment, would be lowered. If such 
conditions were occurring, norepinephrine levels would approach 
I 
a depleted state over a period of time, while dopamine levels 
would be elevated. To investigate this possibility, a study 
was undertaken in which norepinephrine and dopamine levels 
· were measured in animals pretreated with JB835-DOPA combination 
given DFP, 1.0 mg/kg, at intervals of one, two and three hours 
following DFP. The 1.0 mg/kg dose of DFP was used as in the 
course of this long-time experiment, the larger dose of DFP 
induced delayed toxicity which may have effected, nonspecifically, 
the results. 
In the case of the midbrain-diencephalon, one hour following 
DFP, norepinephrine levels were 75 percent of those levels in 
rabbits pretreated with only JB835 and DOPA (Figure 11). 
Dopamine levels at one hour were only slightly elevated over 
those treated with JB835 and D~PA. Two hours following DFP, 
however, both the decrease in norepinephrine and elevation 
in qopamine levels became more apparent; norepinephrine levels 
20 percent less than one hour after DFP, while dopamine levels 
Were 45 percent above the one hour levels. It would appear 
that the time shift on the maximal effect due to 1.0 mg/kg of 
pm/gm 1.00 
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LEGEND FOR.FIGURE 11 
Effect of JB835 (6 mg/kg, ip) and DOPA (50 mg/kg, ip), with 
or without DFP (1.0 mg/kg, sc) on midbrain-diencephalon 
norepinephrine and dopamine levels. Amine levels were measured 
at 1, 2, and 3 hours following DFP. Values are expressed as 
the Mean + the standard error and represent 3-8 individual 
determinations. Control levels (not shown) are 0.336 + 0.035 
and 0.257 + 0.045 for norepinephrine and dopamine respectively. 
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pFP as compared to that of 2.5 mg/kg dose of DFP, might reflect 
a slower rate of cholinesterase inhibition and relatively lower 
acetylcholine levels. Three hours following DFP, the nor-
epinephrine levels were no longer decreasing, but rather 
increasing (Figures 11 and 12). Similarly, dopamine levels 
stopped increasing and were on the decline (Figures 11and12). 
I 
It has been reported that the time required for conversion 
of dopamine to norepinephrine by dopamine-.4-hydroxylase is 
much longer, than that needed for the conversion of dopamine 
from DOPA, (hours versus minutes, Spector et al., 1959). It 
is interesting that one hour following the maximum dopamine 
elevation the norepinephrine levels began to increase. Since 
norepinephrine levels did not continue to decrease to a 
depleted state and dopamine levels declined three hours 
following DFP, it may be concluded that the DFP-induced decrease 
in norepinephrine and elevation in dopamine is not due to 
inhibition of dopamine-~-hydroxylase by DFP. 
The effects observed in the caudate nucleus (Figure 12) at 
various times after 1.0 mg/kg of DFP in rabbits pretreated 
with JB835 and DOPA differed markedly from the effects seen in 
" 
the midbrain-diencephalon region. Norepinephrine levels 
continuously decreased one, two, and three hours following 
DFP. One hour following DFP, the caudate nucleus dopamine· 
levels were slightly lower than the levels in rabbits treated 
with only JB835 and BOPA. Two hours following DFP a 40 percent 
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LEGEND FOR FIGURE 12 / 
Effect of JB835 (6 mg/kg, ip) and DOPA (50 mg/kg, ip), with 
or without DFP (1.0 mg/kg, sc) on caudate nucleus norepinephrine 
and dopamine levels. Amine levels were measured at 1, 2, and 
3 hours following DFP. Values are expressed as the Mean + 
the standard error and represent 3-10 individual determinations. 
Control levels (not shown) are 0.328 + 0.069 and 6.004 + 
0.579 for norepinephrine and dopamine respectively. 
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reduction from the one hour levels was observed. Three hours 
following DFP, the dopamine levels stopped decreasing and a 
3o percent increase over the two hour levels occurred. It 
is interesting that the lowered dopamine levels in the caudate 
nucleus at two hours were further reflected in the lowered 
-
norepinephrine levels at three hours. If one were to compare 
/ 
the time course of the changes in caudate nucleus dopamine 
with the time course of the changes in norepinephrine in the 
.!!Y-dbrain-diencephalon (cf. Figures 11and12), a striking 
similarity can be seen. As dopamine is particularly present 
in the caudate nucleus and norepinephrine in the midbrain-
diencephalon, one may suggest that the DFP-induced response, 
observed with caudate nucleus dopamine and midbrain-diencephalon 
norepinephrine, is characteristic of the transmitter most 
readily released. 
Further studies with quaternary atropine. 
Studies using atropine methyl nitrate alone or with,DFP in 
midbrain-diencephalon indicate (Figure 13) that ATMN alone 
caused a slight elevation in norepinephrine levels compared 
' to levels of norepinephrine in control (no drug) animals: on 
the other hand, AT.MN had no.effect on dopamine. Similar 
results were also observed in the case of the caudate nucleus: 
norepinephrine and dopamine levels with AT.MN were similar to 
. those levels observed in control rabbits (Figure 14). From 
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LEGEND FOR FIGURE 13 
Effect of DFP (2.5 mg/kg, sc); and Atropine methyl nitrate 
(2.0 mg/kg, ip), with or without DFP (2.5 mg/kg, sc) on 
rnidbrain-diencephalon norepinephrine and dopamine levels. Values 
are expressed as the Mean + the standard error and represent 
2-4 individual determinations. control levels are indicated 
by the horizontal line. Significance was calculated using 
Student's test. 
• indicates P(0.025 for the difference between lower bargraphs 
2 and 3; + indicates P(0.10-0.05 for the difference between 
upper bargraphs 2 and 3. 
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LEGEND FOR FIGURE 14 
Effect of DFP (2.5 mg/kg, sc); and Atropine methyl nitrate 
(2.0 mg/kg, ip), with or without DFP (2.5 mg/kg, sc) on 
caudate nucleus norepinephrine and dopamine levels. Values 
are expressed as the Mean + the standard error and represent 
2-4 individual determinations. Control levels are indicated 
by the horizontal line. 
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these results it can be concluded that AT.MN block of the DFP-
induced elevation of dopamine observed in the midbrain-diencephalon 
of rabbits pretreated with JB835-DOPA-ATMN-DFP (2.5 mg/kg) 
combination was not due to ATMN itself, but rather to the 
combination ATMN-DFP. Whether JB835 with DOPA influenced 
this response is yet to be seen. 
ATMN was therefore combined with DFP (2.5 mg/kg) to determine 
the validity of the above conclusion. The results indicate 
that in the case of the midbrain-diencephalon, the DFP-induced 
decrease of norepinephrine levels were unaffected by AT.MN 
treatment which was similar to the observations with AT.MN in 
the case of the JB835-DOPA-DFP combination (Figures 10 and 13). 
Moreover, ATMN was able to block the DFP-induced elevation of 
dopamine (Figure 13), in the absence of the JB835-DOPA pre-
treatment in confirmation of the earlier findings (Figure 10); 
and this fact rules out in addition, any influence of JB835 
and DOPA on this response. ATMN had little, if any, effect 
upon dopamine levels in caudate nucleus in response to DFP 
(Figure 14) • 
It could be then concluded, that in the case of the midbrain-
diencephalon region the action of the quaternary methylatropine 
is responsible for the block in the DFP-induced elevation in 
dopamine levels. 
The above results with ATMN-DFP combinations suggest that 
a peripheral involvement is responsible for the elevation 
110 
.. in dopamine by DFP: on the other hand, the decrease in 
:, norepinephrine levels by DFP, which was unaffected by ATMN, 
seems to be the result of central actions of DFP. If a central 
release mechanism is the means by which DFP produces the 
observed decrease in norepinephrine levels in ~idbrain-dienceph-
el.Qll• it seems unlikely that this effect should concern only 
one catecholamine, and dopamine would be expected to be 
susceptible to this releasing effect also. However, any 
release in dopamine centrally by DFP would be masked by the 
postulated peripheral effect of DFP leading to elevated 
central levels of dopamine. The possibility, in addition, has 
not been eliminated that DFP itself may stimulate dopamine 
synthesis in the brain and thus produce the elevated levels 
of dopamine. 
In the presence of the blockade of both the central and 
peripheral cholinoceptive sites an elevation in dopamine levels 
following this block and a decrease in norepinephrine 
levels by DFP would indicate a direct action of DFP itself. 
Experiments were therefore carried out to determine DFP's 
central actions. Whether DFP, centrally, induces (1) the direct 
' 
release of both norepinephrine and dopamine, the original 
level of the latter being elevated due to DFP's proposed 
peripheral influence, or (2) the release of only norepinephrine 
While stimulating dopamine synthesis leading to elevated 
levels of dopamine, should be determined from these experiments. 
DFP's peripheral influence on dopamine levels is proposed 
111 
to be the result of increased synthesis of dopamine from DOPA. 
Therefore, in the absence of an excess of DOPA, this peripheral 
influence would be minimal. Further, if both the central 
and peripheral atropine-sensitive sites were blocked by 
atropine, thereby eliminating both the central actions of DFP 
(release of norepinephrine), as well as the peripheral 
influences of DFP (elevation of dopamine levels), then any 
actions of DFP on the rnonoamines would indicate that DFP, itself, 
was responsible for the monoarnine responses and that these 
responses were not due to Ach acting on the atropine-sensitive 
cholinoceptive sites. 
Midbrain-diencephalon norepinephrine levels were decreased 
by 50 percent in the case of animals pretreated with JB835 
prior to the administration of DFP, compared to the norepinephrine 
levels in those receiving only JB835 (Figure 15). Furthermore, 
DFP caused a greater than 50 percent increase in dopamine 
levels in the midbrain-diencephalon compared to that observed 
in "loaded" rabbits given DFP (cf. Figure 2). In the rabbits 
pretreated with JB835, AtSO (4.0 mg/kg) given prior to DFP 
4 
blocked the OPP-induced decrease in norepinephrine, the 
norepinephrine levels in the atropine-treated animals being 
comparable to the norepinephrine levels in JB835-treated 
animals (Figure 15). From these results it is concluded that 
the DFP-induced norepinephrine decrease is not a direct action 
Of DFP itself, as blockade by atropine would not occur if 
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LEGEND FOR FIGURE 15 
Effect of JB835 (6 mg/kg, ip) with or without DFP (2.5 mg/kg, 
sc), or Atropine sulfate (4.0 mg/k.g, ip) and DFP (2.5 mg/kg, sc) 
on midbrain-diencephalon norepinephrine and dopamine levels. 
f Values are expressed as the Mean + the standard error and 
f 
t 
~ ~ 
represent 4-6 individual determinations. Control levels (not 
~ 
' 
shown) are 0.336 + 0.035 and 0.257 + 0.045 for norepinephrine 
,. 
f. 
' and dopamine, respectively. Significance was calculated using 
Student's test. 
• indicates P<0.10-0.05 for the difference between both the 
upper and lower bargraphs 1 and 2. 
' 
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pFP'S action was direct. 
In addition, the midbrain-diencephalon dopamine levels 
in rabbits pretreated with JB835 and given AtSO (4.0 mg/kg) 
4 
prior to DFP were not as elevated as in the case of the 
. JB835-DFP treated rabbits. The dopamine levels in the atropine 
treated animals were similar to the dopamine levels in the 
JB835 treated animals. As with norepinephrine, the DFP-induced 
elevation of dopamine in the midbrain-diencephalon appears 
then not to result from direct stimulation of dopamine itself, 
but to be induced by the ~pheral action of DFP. 
Results concerning the caudate nucleus were not so clear. 
Norepinephrine levels following the various treatments were 
similar to those observed in the case of the midbrain-diencephalon. 
DFP caused a decrease in norepinephrine levels in JB835 
pretreated animals compared to norepinephrine levels of the 
rabbits treated with JB835 alone. In addition, AtSO (4.0 
4 
mg/kg} blocked this DFP-induced decrease, the norepinephrine 
levels being similar to that observed in the case of the 
"loaded" animals given DFP (cf. Figure 1). However, in the 
case of the caudate nucleus, Df P given to JB835-pretreated 
rabbits caused not an elevation but a slight decrease in 
dopamine levels. Further, AtSO given prior to DFP in JB835 
4 
Pretreated rabbits caused dopamine levels in the caudate 
~ nncleus to decrease even more (Figure 16). This response to 
lt atropine is unlike that observed in the case rabbits given AtSO (2.0 mg/kg) prior to DFP 4 of the "loaded" (cf. Figure 7), 
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LEGEND FOR FIGURE 16 
Effect of JB835 (6 mg/kg, ip) with or without DFP (2.5 mg/kg, 
sc), or Atropine sulfate (4.0 mg/kg, ip) and DFP (2.5 mg/kg, sc) 
on caudate nucleus norepinephrine and dopamine levels. Values 
are expressed as the Mean + the standard error and represent 
4-5 individual determinations. Control levels (not shown) are 
0.328 + 0.069 and 6.004 + 0.579 for norepinephrine and dopamine, 
respectively. Significance was calculated using Student's test. 
• indicated P{0.10-0.05 for the difference between bargraphs 
1 and 2. 
' 
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where a slight block of the decrease in dopamine occurred. These 
;observed differences may be due to the difference in the 
pretreatments. 
!Pe effects of DFP on catecholamines of brain-parts. 
Thus far all experiments have been carried out with regard 
to midbrain-diencephalon and caudate nucleus. It has been 
demonstrated that DFP given to animals pretreated with JB835 
and DOPA caused a significant decrease in norepinephrine levels 
in the midbrain-diencephalon, while at the same time significantly 
elevated dopamine levels in this area. Atropine sulfate 
given prior to the DFP in JB835-DOPA pretreated animals blocked 
both the norepinephrine decrease and the dopamine increase. 
Atropine methyl nitrate given prior to DFP in animals pre-
treated with JB835 and DOPA blo.cked only the dopamine elevation, 
suggestive of peripheral involvement. 
l 
These responses were 
most pronounced in the midbrain-diencephalon area compared to 
those obtained in the case of the caudate nucleus. Therefore, 
additional experiments were carried out to determine whether. 
specific areas within the midbrain-diencephalon region, i.e. 
' midbrain, thalamus, and hypothalamus, could all exhibit the 
DFP responses, namely a decrease in norepinephrine levels and 
an increase in dopamine levels. An additional area, the hippo~ 
campus, was also selected to demonstrate DFP's effects on a 
I non-midbrain-diencephalon area. 
~. 
t 
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Mean norepinephrine levels in the thalamus, the hypothalamus, 
:the midbrain, and the hippocampus were decreased by DFP (2.5 
mgfkg) in rabbits pretreated with JB835 and DOPA when compared 
to norepinephrine levels in the animals receiving only JB835 
and DOPA. Forty two, 13, 25, and 16 percent decreases in 
, norepinephrine were observed in the thalamus, hypothalamus, 
midbrain, and in the hippocampus, respectively (Figure 17). 
Thus, the responise to DFP was not restricted to any one specific 
" 
area. The fact that this response to DFP was non-localized 
might have been predicted based on the reported presence of 
. 
, both cholinoceptive and adrenergic neurons within these brain 
areas. 
Addition of ATMN prior to DFP in rabbits pretreated with 
' JB835 and DOPA had no effect upon DFP's ability to decrease 
norepinephrine levels. In both the thalamus and mid.brain, the 
levels of norepinephrine following the JB835-DOPA-ATMN-DFP 
r combination were nearly identical with those in the case of 
l rabbits treated with the JB835-DOPA-DFP combination. In the 
hypothalamus and hippocampus ATMN given prior to DFP in JB835-
DOPA pretreated rabbits 9aused,a further reduction in norepin-
ephrine levels (25 and 21 percent, respectively} compared to 
the norepinephrine levels following JB835-DOPA-DFP combinations. 
The order of responses observed in these four brain areas 
! is identical with that of the norepinephrine responses in the l Midbrain-diencephalon (Figure 10). 
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LEGEND FOR FIGURE 17 
Effect of JB835 (6 mg/kg, ip) and DOPA (SO mg/kg, ip), with 
or without DFP (2.5 mg/kg, sc), or Atropine methyl nitrate 
(2.0 mg/kg, ip) and DFP (2.5 mg/kg, sc) on norepinephrine levels 
in the thalamus, the hypothalamus, the midbrain, -and the 
hippocampus. Values are expressed as the Mean + the standard 
error and represent 3-4 individual determinations. Control 
levels for each brain part are indicated by the horizontal line. 
Stati.stical significance was calculated using Student's test. 
+ indicates P<0.05 for the difference between bargraphs 1 and 
2 in the thalamus; • indicates P(0.10-0.05 for the difference 
between bargraphs 1 and 2 in the rnidbrain. 
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DFP given to animals pretreated with JB835 and DOPA caused 
an elevation of dopamine levels in the thalamus, the hypo-
thalamus, the midbrain, and the hippocampus compared to 
dopamine levels of the animals treated with JB835 and DOPA 
' (Figure 18). A 35, 311, 57, and 6 percent increase was 
observed in the case of the thalamus, hypothalamus, midbrain, 
and hippocampus respectively; the effects recorded in the 
" case of the hypothalamus and midbrain were statistically 
significant. As in the case of norepinephrine, the DFP-induced 
elevation in dopamine levels within these four brain areas was 
of identical order with that of the dopamine responses due 
to DFP in the midbrain-di.encephalon (Figure 10). Moreover, the 
DFP-induced dopamine elevation occurred in the midbrain-
diencephalon, as well as in the non-midbrain-diencephalon 
area, indicating a non-localized effect of DFP. 
The administration of ATMN prior to DFP in rabbits pretreated 
with JB835 and DOPA caused a block in the elevation of dopamine 
by DFP in all four brain areas (Figure 18). In the thalamus, 
a significant 87 percent reduction in dopamine levels occurred 
compared to the dopamine level~ in the case of the rabbits 
treated with JB835-DOPA-DFP combination; in the hypothalamus, 
. midbrain, and hippocampus, decreases of 55, a significant 58, 
! and 34 percent, respectively, were noted. Again, the degree 
i ~ t Of the blocking effect of ATMN on the DFP-induced elevation in l dopamine levels in these four brain areas was identical with 
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LEGEND FOR FIGURE 18 
Effect of JB835 (6 mg/kg, ip) and DOPA (50 mg/kg, ip), with 
or without DFP (2.5 mg/kg, sc), or Atropine methyl nitrate {2.0 
mg/kg, ip) and DFP (2.5 mg/kg, sc) on dopamine levels in the 
thalamus, the hypothalamus, the mid.brain, and the hippocampus. 
Values are expressed as the Mean + the standard error and represent 
3-4 individual determinations. Control levels for each brain 
part are indicated by the horizon~al line. Statistical 
significance was calculated using Student's test. 
o indicates P<0.01 for the difference between bargraphs '2 and 
3 in the thalamus; e indicates P(0.10-0.05 for the difference 
between bargraphs 1 and 2 in the hypothalamus; + and • indicates 
P(0.05 and P(0.025 for the differences between bargraphs 1 and 
' 2, and 2 and 3, respectively, in the mid.brain. 
' ,' 
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tnat observed in the case of the midbrain-diencephalon (cf. 
Figure 10) . 
These and earlier data presented strongly suggest that the 
blocking action of ATMN on the DFP-induced elevation in 
dopamine levels observed in the midbrain-diencephalon occurs 
at the peripheral cholinoceptive sites otherwise stimulated 
by the DFP-induced elevation in acetylcholine. 
The effects of the intraventricular administration of DFP. 
Data thus far obtained suggest a central, as well as a 
peripheral action of DFP. However, it is difficult to separate 
DFP's central releasing effect from its peripheral dopamine 
elevating effect. Using ATMN, it was possible to block the 
peripheral elevating effect of PFP, but it could not be 
determined whether DFP, in addition to this action, was 
influencing the central amines through stimulation of non-
atropine sensitive sites. If DFP were administered via the 
intraventricular rather than the subcutaneous route, the 
central actions of DFP could be more easily observed, being 
"divorced" under these circumstances from the peripheral 
influences. 
of 
Previous investigators have used intraventricular injection 
of drugs, i.e. acetylcholine, carbachol, norepinephrine, which 
have both peripheral and central actions, to separate the central 
from the peripheral responses to these agents (Feldberg, 1963; 
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Feld.berg, 1958; Grossman, 1968: and Stein, 1970). The majority 
of these studies were investigating behavorial responses 
to central stimulation by the various drugs, in an attempt 
to identify the brain areas involved in producing these responses 
!·.·.:·······. and, in addition, the types of neurons, i.e. cholinergic or adrenergic, involved. 
Injection of lOOµg of DFP into the lateral ventricle of 
cat was carried out by Feldberg {1958). Three symptomological 
stages, which overlapped, were reported. The first stage 
had consisted of severe itching, wiping of the face and forelegs, 
and vigorous licking and chewing motion of the jaws. Itching 
is a characteristic sign of anticholinesterase action, probably 
resulting from inhibition of cholinesterase and subsequent 
accumulation of acetylcholine in the tissues lining the 
ventricular walls. During the second stage, increased tone 
and tremor of skeletal muscle occurred. The first two stages 
were relatively short in appearance while the third stage lasted 
longer. The third stage was characterized by an alteration of 
awareness and the development of stupor and catatonia. In 
this condition, the cats coulq be placed in abnormal positions 
which they retained for some minutes. Similar signs of 
catatonia were observed when eserine or large doses of acetyl-
choline were injected intraventricularly. 
Rabbits given 200pg of DFP via the intraventricular route 
in the present study exhibited similar signs. The initial 
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excitement stage was characterized by either clockwise or 
counter-clockwise spinning movements; each animal spinning 
in only one direction. The rabbits subsequently developed 
a_ tonic type of kicking, and tremors. The last stage, begin-
ning about 10 minutes after the injection, was characterized 
by a chewing jaw motion while the animals were lying in a 
resting position. Frequently the animals would rock from side 
to side. In a few cases the rabbits were up on all four legs 
in a catatonic-like stance moving their head from side to side. 
This stance lasted, however, only for 5 or 10 minutes. Pinpoint 
pupils, severe salivation, and foreleg muscle fasciculations 
were not as apparent as they were when DFP was given by the 
subcutaneous route. These behavorial responses in rabbits to intra-
ventricular injection of DFP were identical in many respects to 
those responses observed in cats treated similarly. 
In the initial experiments, the procedures of which are 
described in the Methods, the rabbits were anesthetized with 
sodium pentoba.rbital. The results obtained (Figures 19 and 20) 
with regard to the midbrain-diencephalon and caudate nucleus 
in the rabbits given JB835 an~DOPA and not DFP, indicate 
that the pentobarbital was interfering with the normal uptake 
and release mechanisms for both norepinephrine and dopamine. 
As can readily be seen, the norepinephrine levels in both brain 
areas in the case of the sham controls (given JB835-DOPA-Saline 
: . 
combination) were considerably more elevated than the norepinephrine i levels in animals similarly treated but not anesthetized (Tables 
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LEGEND FOR FIGURE 19 
Effect of intraventricular injection of DFP (200µg) or Saline 
on norepinephrine and dopamine levels in rabbit midbrain-
diencephalon with and without pentobarbital anesthesia following 
pretreatment with JB835 (6 mg/kg, ip) and DOPA (SO mg/kg, ip), 
or JB835-DOPA-and ATMN (2.0 mg/kg, ip). Values are expressed 
as the Mean + the standard error and represent 3-4 individual 
determinations. Statistical significance was calculated using 
Student's test. 
o indicates P(0.025 for the difference between bargraphs 1 and 
2; ~ indicated P~0.005 for the difference between bargraphs 
1 and 3. 
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LEGEND FOR FIGURE 20 
Effect of intraventricular injection of DFP (200pg) or 
Saline on norepinephrine and dopamine levels in rabbit caudate 
nucleus with and without pentobarbital anesthesia following 
pretreatment with JB835 (6 mg/kg, ip) and DOPA (50 mg/kg, ip), 
or JB835-DOPA- and ATMN (2.0 mg/kg, ip). Values are expressed 
as the Mean + the standard error and represent 3-4 individual 
determinations. Statistical significance was calculated using 
Student's test. Statistical significance (P(O.OS)was found 
for the difference between the upper bargraphs 2 and 3. 
' 
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1 and 2). Similar results were observed in the case of the 
dopamine levels. Maynert and Levi (1964) reported that sodium 
pentobarbital prevented the morphine-induced decline in brain-
stem norepinephrine in cats, which led to elevated norepinephrine 
levels. It appeared that in the case of our intraventricular 
studies, pentobarbital acted in a similar manner. Therefore, 
additional experiments were performed using unanesthetized 
rabbits. 
DFP (200pg) injected into the left lateral ventricle in 
rabbits pretreated with;JB835 and DOPA, caused a marked 33 
percent decline in norepinephrine levels in the midbrain-
diencephalon (Figure 19) relative to the norepinephrine levels 
observed in the case of the rabbits treated with JB835-DOPA-
Saline combinations (sham controls). Although the intra-
ventricular dose of DFP differed from that previously given 
s.c. (2.5 mg/kg), the response induced by DFP was identical, 
indicating that the releasing action of DFP was centrally 
mediated. A similar decrease in norepinephrine levels was 
observed in the pentobarbital anesthesized rabbits, although 
the overall levels of norepinephrine were higher. AT.MN given 
prior to the intraventricular administration of DFP to rabbits 
pretreated with JB835 and DOPA had no effect on the DFP-induced 
decrease in norepinephrine levels observed in the case of the 
rabbits treated with JB835-DOPA-DFP (intraventricular) combinations. 
This inability of AT.MN to block the decrease in norepinephrine 
produced by DFP via the intraventricular route is identical with 
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the effects observed of ATMN on the DFP-induced decrease in 
norepinephrine observed in the midbrain-diencephalon when DFP 
was given s.c. (cf. Figure 10). ATMN was incapable of blocking 
the actions of DFP on norepinephrine levels, whether DFP was 
administered via the s.c. or intraventricular routes. 
Dopamine levels in the midbrain-diencephalon of non-anesthetized 
rabbits, pretreated with JB835 and DOPA were not significantly 
different from the dopamine levels in the case of the rabbits 
given JB835-DOPA-Saline combinations; the dopamine levels 
were slightly but not significantly higher (Figure 19) 
following DFP. In similarly treated rabbits anethetized with 
pentobarbital, a marked decrease in dopamine levels by DFP 
was observed; however, it should be remembered that the dopamine 
levels in anesthetized rabbits were higher than those observed 
in unanesthetized rabbits. 
The lack of elevated dopamine levels induced by DFP via the 
intraventricular route, as opposed to the significant elevation 
in dopamine levels induced by DFP via the subcutaneous route, 
-------seems to indicate that the latter effect is due to the peripheral, 
not central, action of DFP. 
' Further support for this conclusion was obtained .in the 
experiments in which ATMN was given prior to the intraventricular 
administration of DFP in rabbits pretreated with JB835 and DOPA. 
The levels of dopamine in the midbrain-diencephalon did not 
differ significantly from the levels of dopamine in either the 
rabbits given the JB835-DOPA-Saline combination, or the JB835-
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pOPA-DFP (intraventricular) combination. Thus, DFP administered 
via the intraventricular route had no effect upon the dopamine 
1evels in either JB835, DOPA pretreated animals or in those 
receiving, in addition, AT.MN. These results were in sharp 
opposition to those observed in the experiments in which DFP 
was administered via the subcutaneous route; they firmly 
support the notion of the peripheral action of DFP involved 
in producing the elevation in dopamine levels within the 
midbrain-diencephalon. 
As expected, in the caudate nucleus, the response to the 
intraventricular injection of DFP (200µg) was not well defined. 
This was typical of the caudate nucleus as the lack of conformity 
with those results obtained in the case of the midbrain-
diencephalon was observed in the earlier experiments. Norepinephrine 
levels, in unanesthetized rabbits pretreated with JB835 and DOPA 
given DFP (200pg) intraventricularly, were not different from 
norepinephrine levels in animals treated with JB835-DOPA-Saline 
combination (Figure 20). In animals treated similarly, but 
not anesthetized with pentobarbital, there was a 29 percent 
though not significant, decrease in the norepinephrine levels 
' 
in the DFP treated animals compared to those without DFP. 
AT.MN given to unanesthetized animals pretreated with JB835 and 
DOPA followed by DFP intraventricularly produced a significant 
(P~0.05) 38 percent decrease in norepinephrine levels compared 
to the norepinephrine levels in the case of the animals treated 
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with the JB835-DOPA-DFP (intraventricular) combination. Dopamine 
f. 1evels in caudate nucleus were n?t significantly different 
~ 
in rabbits treated with : JB835-DOPA-Saline combination; JB835-
DOPA-DFP (intraventricular) combination; or JB835-DOPA-ATMN-
DFP (intraventricular) combination. However, there was a 15 
percent (not significant) increase in dopamine levels observed 
in the case of the rabbits treated with JB835-DOPA-DFP combination 
compared with the animals receiving JB835-DOPA-Saline combination 
(Figure 20). A similar increase in dopamine levels was observed 
in anesthetized rabbits treated with JB835-DOPA-DFP (intra-
ventricular) combination. 
The effect of DFP on cholinesterases and on acetylcholine. 
The assumption that because DFP is a potent anticholinesterase 
the rabbit brain cholinesterases will be inhibited following 
DFP administration is not a valid assumption without direct 
evidence of such inhibition. It was for this purpose that 
experiments, measuring the percent of cholinesterase (total 
acetylcholinesterase~and 25 percent of butrylcholinesterase) 
inhibition produced by DFP (2.5 mg/kg) in the thalamus, the 
' hypothalamus, the mid.brain, and the caudate nucleus were 
performed. Rabbits were treated, as described in the Methods, 
with the following combinations: JB835-DOPA; JB835-DOPA-DFP: 
JB835-DOPA-AtSO -DFP; and a no-drug control group was also 
' 4 
employed. Their cholinesterase activity was measured in terms 
of the Rate of Hydrolysis (Moles of substrate hydrolyzed/ minute 
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/ gram of tissue) of cholinesterase. 
Cholinesterase activity in the thalamus, the hypothalamus, 
the mid.brain, and the caudate nucleus of rabbits treated 
with JB835 and DOPA was almost identical (not significantly 
different) to the cholinesterase activity in control (no drug) 
animals (Table 3). These results indicate that JB835 and 
DOPA are without effect upon the activity of cholinesterase 
in these four brain areas. The data further confirms the 
reported findings that the cholinesterase activity is highest 
in the caudate nucleus and mesencephalon (mid.brain) regions 
of the brain (Votava, 1967 and Karczmar, 1967), the mean rate 
being 0.22 X 10 
-4 -4 
for the caudate nucleus and 0.12 X 10 
-4 
the mid.brain as compared to 0.07 X 10 
-4 
for the thalamus 
for 
and 0.10 X 10 for the hypothalamus (for S.E. 's cf. Table 3). 
Using the cholinesterase activity in the rabbits treated 
with JB835 and DOPA (sham controls) to represent zero percent 
inhibition it was found that the addition of DFP (2.5 mg/kg) 
to rabbits pretreated with JB835 and DOPA produced a 96.30 
percent inhibition of cholinesterase activity, or greater, 
in the caudate nucleus, the mid.brain, the thalamus, and in the 
' 
hypothalamus (Figures 21 and 22). Similar results were obtained 
when AtSO was given prior to DFP in rabbits pretreated with 
4 
JB835 and DOPA, the percent of brain cholinesterase inhibition 
being 97.50 or greater in the four brain areas. Thus the 
administration of DFP (2.5 mg/kg) did produce nearly 100 
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TABLE 3 
CHOLINESTERASE ACTIVITY IN RABBIT BRAIN PARTS 
control (no drug) 
JB835-DOPA 
JB835-DOPA-DFP 
JB835-DOPA-AtSO -DFP 
4 
' 
-4 
Mean Rate* of Substrate Hydrolysis 
+ Standard Error 
Caudate N. Midbrain Thalamus 
+ 
0.22+ 0.01 0.12+ 0.01 0.07+ 0.00 
0.22+ 0.01 0.13+ 0.01 0.06+ 0.02 
0.00+ 0.00 0.00+ 0.00 0.00+ o.oo 
0.00+ 0.00 0.00+ 0.00 0.00+ 0.00 
Hypothalamus 
0.10+ 0.02 
0.08+ 0.02 
0.00+ 0.00 
0.00+ 0.00 
+ All values are X 10 and represent the mean of two determinations. 
* Rate= Moles of substrate hydrolyzed/minute/gm. tissue. 
Doses used: JB835, 6 mg/kg, ip; DOPA, 50 mg/kg, ip; DFP, 2.5 
mg/kg, sc; AtSO , 2.0 mgjkg, ip. 
4 
No statistically significant difference was found between the 
cholinesterase activity of the control and JB835-DOPA combinations 
in any of the four brain areas. Statistical significance was 
' found between the JB835-DOPA combination and each of the DFP 
containing combinations; the significance being in the caudate 
nucleus and midbrain P(0.005; in the thalamus P(0.10-0.05; and 
in the hypothalamus P<O;o5. 
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LEGEND FOR FIGURE 21 
Percent of cholinesterase inhibition by DFP (2.5 mg/kg, sc) 
in the caudate nucleus and midbrain of rabbit following 
pretreatment with JB835 (6 mg/kg, ip) and DOPA (50 mg/kg, ip), 
or JB835-DOPA- and Atropine sulfate (2.0 mg/kg, ip). JB835-
DOPA combination represents zero percent inhibition of cholinesterase 
activity. Values represent the mean of two assays. Statistical 
significance was calculated using Student's test. P(0.005 
significance was found for the difference between bargraphs 
1 and 2, and 1 and 3 for the caudate nucleus and the midbrain. 
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LEGEND FOR FIGURE 22 
Percent of cholinesterase inhibition by DFP (2.5 mg/kg, sc) 
in the thalamus and the hypothalamus of rabbit following 
pretreatment with JB835 (6 mg/kg, ip) and DOPA (SO mg/kg, ip), 
or JB835-DOPA- and Atropine sulfate (2.0 mg/kg, ip). JB835-
DOPA combination represents zero percent inhibition of cholinesterase 
activity. Values represent the mean of two assays. Statistical 
significance was calculated using Student's test. P~0.10-
0.05 was found for the difference between bargraphs 1 and 2, 
and 1 and 3 for thalamus; P<0.05 was found for the difference 
between bargraphs 1 and 2, and 1 and 3 for the hypothalamus. 
' 
r. 
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. percent cholinesterase inhibition in rabbits pretreated with 
JB835 and DOPA, or with JB835, DOPA, and AtSO • It is also 
4 
evident that AtSO does not interfere with DFP's ability to 
4 
inhibit cholinesterase. 
While the above data suggest that DFP should have elevated 
acetylcholine levels, as cholinesterases are the enzymes 
responsible for the hydrolysis of the latter, it was still 
necessary to demonstrate directly that indeed DFP (2.5 mg/kg, 
sc) elevated the levels of acetylcholine in the caudate nucleus, 
midbrain, thalamus, and hypothalamus in rabbit. Using bioassay 
techniques, acetylcholine levels were assayed in two samples 
each of the four brain areas for each drug combination. There 
was little difference between acetylcholine levels of the 
rabbits receiving the JB835 and DOPA treatment as compared to 
the levels found in the control rabbits in the case of the 
caudate nucleus, midbrain, thalamus, or hypothalamus (Table 
4). Taking the acetylcholine levels in the caudate nucleus, 
midbrain, thalamus, and hypothalamus of control (no drug) 
rabbits as representing 100 percent of acetylcholine it was 
found that, of the four brain'areas from the animals treated 
with JB835 and DOPA, the midbrain exhibited the greatest 
deviation from its respective control acetylcholine level1 
this deviation was only 11 percent (Figures.23-26). It was, 
in addition, found that neither JB835 nor DOPA had any 
·~ignificant effect, compared to the control rabbits, upon 
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TABLE 4 
EFFECT OF DRUGS ON ACETYLCHOLINE LEVELS IN RABBIT BRAIN PARTS 
Acetylcholine ug/gm. 
Q_rugs caudate N. Midbrain Thalamus Hypothalamus 
control ·{no drugs) 2.02 1.35 1.35 1.06 
2.19 1.21 1.53 1.00 
NS NS NS NS 
JB835-DOPA 1.88 1.40 1.82 . 1.01 
1.93 1.43 1.38 1.03 
+ 0 0 • 
DFP 5.59 4. 39 4.08 4.13 
4.36 5.76 4.70 4.64 
JB835-DOPA-DFP 5.00 4.78 3.62 3.25 
6.30 4.08 3.47 3.50 
JB835-DOPA-AtSO -DFP 5.89 3.67 2.81 2.68 
4 4.80 3.56 3.17 3.01 
JB835-DOPA-ATMN-DFP 4.73 4.39 3.96 3.49 
4.28 5.10 3.07 3.46 
Values represent individual bioassays. Doses used: JB835, 6 
mg/kg, ip; DOPA, 50 mg/kg, ip; DFP, 2.5 mg/kg, sc; AtSO , 2.0 
4 
mg/kg, ip; ATMN, 2.0 mg/kg, ip. Statistical significance 
' was calculated using Student's test.· 
+ indicates P<0.05 for the difference between the two groups; 
o indicates P(0.025 for the difference between the two groups; 
• indicates P(0.005 for the difference between the two groups. 
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LEGEND FOR FIGURE 23 
Percent of acetylcholine increase over control (no drug) 
acetylcholine levels in the rabbit caudate nucleus followhg 
JB835 (6 mg/kg, ip) and DOPA (50 mg/kg, ip), or DFP (2.5 mg/kg, 
sc) with or without JB835 (6 mg/kg, ip) and DOPA (50 mg/kg, ip}, 
JB835-DOPA- and Atropine sulfate (2.0 mg/kg, ip), or JB835-
DOPA- and Atropine methyl nitrate (2.0 mg/kg, ip). Percent 
increases are determined from the mean of two individual 
bioassays + the standard error. Control levels are representive 
of 100 percent acetylcholine. Statistical significance was 
calculated using Student's test. 
The difference between the mean values of bargraphs 2 and 3 
was found to be significant (P(0.05). 
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LEGEND FOR FIGURE 24 
Percent increase of acetylcholine over control (no drug) 
acetylcholine levels in the rabbit midbrain following JB835 
(6 mg/kg, ip) and DOPA (50 mg/kg, ip), or DFP (2.5 mg/kg, sc) 
with or without JB835 (6 mg/kg, ip) and DOPA (50 mg/kg, ip), 
JB835-DOPA- and Atropine methyl nitrate (2.0 mg/kg, ip), or 
JB835-DOPA- and Atropine sulfate (2.0 mg/kg, ip). Percent 
increases are determined from the mean of two individual 
bioassays + the standard error. Control levels are representive 
of 100 percent acetylcholine. Statistical significance was 
calculated using Student's test. The difference between the 
mean values of bargraphs 2 and 3 was found to be significant 
(P(0.025). 
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LEGEND FOR FIGURE 25 
Percent increase of acetylcholine over control (no drug) 
acetylcholine levels in the rabbit thalamus following JB835 
(6 mg/kg, ip) and DOPA (SO mg/kg, ip), or DFP (2.5 mg/kg,sc) 
with or without JB835 (6 mg/kg, ip) and DOPA (50 mg/kg, ip)_ 
JB835-DOPA- and Atropine methyl nitrate (2.0 mg/kg,ip}, or 
JB835-DOPA- and Atropine sulfate (2.0 mg/kg, ip). Percent 
increases are determined from the mean of two individual 
bioassays + the standard· error. Control levels are representive 
of 100 percent acetylcholine. Statistical significance was 
calculated using Student's test. The difference between the 
mean values of bargraphs 2 and 3 was found to be significant 
(P(0.025). 
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LEGEND FOR FIGURE 26 
Percent increase of acetylcholine over control (no drug) 
acetylcholine levels in the rabbit hypothalamus following JB835 
(6 mg/kg, ip) and DOPA (50 mg/kg, ip), or DFP (2.5 mg/kg,sc) 
with or without JB835 (6 m~/kg, ip) and DOPA (50 mg/kg, ip), 
JB835-DOPA- and Atropine methyl nitrate (2.0 mg/kg, ip), or 
JB835-DOPA- and Atropine sulfate (2.0 mg/kg, ip). Percent 
increases are determined from the mean of two individual 
bioassays + the standard error. Control levels are representive 
of 100 percent acetylcholine. Statistical significance was 
calculated using Student's test. The difference between the 
mean values of bargraphs 2 and 3 was found to be significant 
(P(0.005). 
' 
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acetylcholine levels in any of the four brain areas. 
DFP (2.5 mg/kg} alone produced increases in acetylcholine 
content compared to its effect in the animals pretreated with 
the JB835-DOPA combination. The percent increases, all of 
which were significant, due to DFP alone were: 297, 205, 
330, and 136 in the midbrain, the thalamus, the hypothalamus, 
and the caudate nucleus, respectively, over the acetylcholine 
levels in identical areas of the JB835-DOPA treated rabbits. 
DFP given to rabbits pretreated with JB835 and DOPA caused 
an elevation in the acetylcholine levels over control acetyl-
choline levels by 168, 246, 146, and 228 percent in the caudate 
nucleus, the mid.brain, the thalamus, and the hypothalamus, 
respectively. When AT.MN was given prior to DFP to JB835 and 
DOPA pretreated animals acetylcholine levels elevated by the 
DFP as compared to control levels were: 114, 271, 144, and 
238 percent in the caudate nucleus, midbrain, thalamus, and in 
the hypothalamus, respectively. 
It. is evident that DFP, whether alone or following pretreat-
ment with JB835 and DOPA or JB835, DOPA, and AT.MN, produced 
marked elevations in acetylcholine levels in these four brain 
• 
areas in rabbit: this then relates well with the demonstration 
of cholinesterase inhibition produced by DFP in these four 
areas (cf. Figures 21 and 22). 
A special comment is required with regard to the last drug 
combination: in this case, atropine sulfate, given prior to 
DFP in rabbits pretreated with JB835 and DOPA, was observed 
l 
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to interfere somewhat with the elevation of acetylcholine 
1evels by DFP. Although this interference was not found to 
be statistically significant, a trend was evident. In the 
midbrain, thalamus, and hypothalamus acetylcholine levels in 
atropine sulfate treated animals were lower following DFP 
than all other DFP containing drug combinations (Figures 24-
26). The only brain area where this effect was was not observed 
was the caudate nucleus, where the acetylcholine levels of 
the atropine sulfate treated animals were were approximately the 
same as the other drug groups containing DFP (Figure 23). 
The observed lessening of DFP~induced elevation of acetylcholine 
levels was, however, anticipated. Mitchell (1963}, Szerb (1964), 
and Polak and Meeuws (1966) demonstrated that atropine sulfate 
enhanced the release of acetylcholine from the cerebral cortex 
of the cat, rabbit, sheep, and rat. Similar results were 
also observed in rats by Hingtgen and Aprison (1970). Thus, 
the observation that in the presence of AtSO , acetylcholine 
4 
levels following DFP were less than those observed in animals 
not pretreated with AtSO , seem reasonable. It would seem that 
4 
AtSO 
4 
caused a lowering of acetylcholine levels through 
I( 
release, and subsequent degradation of acetylcholine by 
cholinesterase, prior to the administration of DFP. Thus, 
with an initial lowered level of acetylcholine, the elevation 
of acetylcholine levels caused by DFP was less in those drug 
combinations where the acetylcholine levels were not initially 
lowered by atropine. It should also be pointed out that this 
153 
effect was not observed following DFP in animals pretreated 
with drug combinations which included ATMN. 
Regardless of the individual variations within each brain 
area, all drug combinations containing DFP (2.5 mg/kg) showed 
acetylcholine levels which were elevated a minimum of 100 
percent over control acetylcholine levels. Altogether, we 
, could demonstrate that DFP at a dose of 2.5 mg/kg, s.c. 
adequately inhibited brain cholinesterase in all four brain 
areas (Table 3), causing marked elevation in the acetylcholine 
levels within these areas (Table 4). 
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DISCUSSION 
The concept of cholinergic-adrenergic coupling is not by 
any means novel. Burn and Rand in 1959 had proposed for the 
peripheral nervous system, a neural mechanism by which acetyl-
choline was able to cause the release of norepinephrine from 
sympathetic nerve terminals. Koelle (1963) modified this 
concept to allow for acetylcholine, having been released 
from a nerve terminal, to act back upon that nerve terminal 
from which it was released, to cause a "percussive" release 
of norepinephrine. 
Considerable evidence has been presented over the years 
which seems to support these concepts. Only recently, however, 
has attention been focused upon the possibility of a cholinergic-
adrenergic mechanism existing in the central nervous system. 
Both electrophysiological and neurochemical evidence 
obtained by Van Meter (1969) and Van Meter and Karczmar (1970) 
suggested an interplay between the central neurotransmitters, 
acetylcholine and norepinephr\pe, in the anticholinesterase 
(eserine) produced blockade of EEG recruitment. Specifically, 
~n rabbits whose norepinephrine levels had been depleted 
by aC.MPT, and related drugs, eserine administration was unable 
to produce blockade of the EEG recruitment. However, following 
replenishment of the norepinephrine stores with DOPA administration, 
' l 
the ability of eserine to block EEG recruitment was restored. 
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Additional evidence of Karczmar and Longo (1970) and Karczmar 
et al. (1971) demonstrated a similar relationship in rabbits 
in the case of the paradoxical sleep phenomena. 
More recently, Philippu (1970) has provided evidence which 
indicates that acetylcholine does, in fact, cause the release 
of norepinephrine from cerebral cortex in cat, provided 
calcium is present. 
Although these findings indicate the possibility for the 
existence of a central cholinergic-adrenergic link, they do 
not provide comprehensive evidence on the transmitter systems 
involved, and the results dealing with acetylcholine, 
norepinephrine, and dopamine, as well as cholinesterases, i.e. 
acetyl-, butrylcholinesterase, etc., remain incomplete. 
The present studies were therefore undertaken to provide 
evidence as to the central effects produced by the anti-
cholineste rase, DFP. The questions to be answered relate to: 
(1) the effect of DFP upon the activity of cholinesterase; 
(2) the subsequent effects upon the levels of acetylcholine due 
to cholinesterase inhibition by DFP; and (3) the effect of DFP 
and/or acetylcholine upon the norepinephrine and dopamine 
levels. In addition, these findings would hopefully provide 
a base from which an understanding of the mechanisms involved 
in central cholinergic-adrenergic coµpling could evolve. 
Measurement of the cholinesterase levels in the midbrain, 
the thalamus, the hypothalamus, and the caudate nucleus confirmed 
r 
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that nearly 100 percent inhibition of cholinesterase activity 
was obtained using the 2.5 mg/kg, sc, dose of DFP, with or 
without pretreatment with JB835 and DOPA. Moreover, results 
on the activity of cholinesterase in control rabbits confirms 
previous findings (Karczmar, 1967, and Votava, 1967) that 
cholinesterase activity is highest within the caudate nucleus 
and the mesencephalon {midbrain) areas in cat, rat, mouse, and 
rabbit. 
With the marked inhibition of cholinesterase activity, 
acetylcholine levels were found to be elevated by this dose 
of DFP. In the midbrain, the thalamus, the hypothalamus, and 
the caudate nucleus, DFP caused a minimum of 100 percent increase 
in the levels of acetylcholine. In no case did the JB835 and 
DOPA pretreatment cause significant differences in the effect of 
DFP on either the cholinesterase activity or on levels of acetyl-
choline. As such, the role of JB835 and DOPA in these experiments 
was restricted to elevating the levels of norepinephrine and 
dopamine which allowed the DFP-induced responses to be more 
readily observed. 
Of possibly greater significance was the lack of effect on 
' 
the acetylcholine levels in the thalamus, the hypothalamus, the 
midbrain, and the caudate nucleus·, of either norepinephrine or . 
dopamine, levels of which were elevated by the administration of 
the JB835-DOPA combination. The postulation of Burn and Ran~, 
as well as that of Koelle, provided for the action of 
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acetylcholine upon the sympathetic nerve terminals to cause 
the release of norepinephrine. As such, their proposal 
provided for cholinergic (acetylcholine) actions upon the 
sympathetic adrenergic (norepinephrine) nerve terminals. However, 
the possibility of adrenergic actions upon cholinergic nerve 
terminals was not considered in either the Burn and Rand or 
Koelle proposals. Until now there has been no reported 
evidence concerning the possibility of an adrenergic-cholinergic 
link. In the present experiments it was demonstrated in 
rabbits that norepinephrine and dopamine in a "loaded" state (that 
is after the monoamine levels were elevated by JB835-DOPA 
pretreatment) did not cause significant changes in the levels 
of acetylcholine in the midbrain, the thalamus, the hypothalamus, 
or the caudate nucleus. These findings are highly significant 
and suggest that the possible mechanism of adrenergic-cholinergic 
coupling does not exist in these rabbit brain areas. 
It should be pointed out, however, that the above conclusion 
was based upon data obtained from animals whose levels of 
monoamines were in a "loaded" state, but whose acetylcholine 
levels were not. The possibility should not be excluded that 
' 
monoamines can exert some type of influence other than a 
coupling phenomena, i.e. competition of the transmitters for 
available storage sites, upon the levels of acetylcholine. 
Evidence obtained from animals given DFP alone or JB835-DOPA-
DFP indicate that in the latter case, the levels of acetylcholine 
r 
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were lower than in the case of the former in the thalamus, 
the hypothalamus, and the midbrain. Similar responses were 
observed in the case of rabbits pretreated with JB835-DOPA-
ATMN- and given DFP compared to those given DFP alone. Although 
these differences were not significant, their trend suggest 
the possibility of monoamine influence upon acetylcholine 
levels when both transmitters are in the "loaded" state. 
The questions that arise are concerned with the mechanisms 
involved in the acetylcholine-catecholamines coupling and 
particularly in the differential effects on dopamine and on 
norepinephrine. 
The present findings demonstrate that in rabbits, DFP given 
systemically, induc:es ·· significant increments of dopamine 
levels and significant decrements of norepinephrine levels in 
the midbrain-diencephalon and to some extent, the caudate nucleus 
regions. These changes, however, could be noted only after 
the levels of these monoamines were increased by appropriate 
pharmacological maneuvers, as DFP did not affect the monoamines 
without prior JB835 and/or DOPA pretreatment. This finding 
suggest that the effects of DFi on the monoamines are best 
observed under optimal conditions for their neuronal synthesis 
and storage. Conversely, in the studies on amine uptake and 
release the results were best observed in animals depleted 
of monoamines by reserpinization (Anden et al., 1964). Of 
course, DFP may have induced less pronounced changes under 
l less favorable conditions as well, which escaped detection 
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by our methods; they may be however revealed by more sensitive 
techniques, as well as, be reflected more readily in the 
change in the monoamine turnover values, which were not studied 
at present. 
One would expect that acetylcholine would exert a similar 
effect on both the monoamines. However, the rate of synthesis 
of dopamine is much higher than that of norepinephrine {Weiner, 
1970), while perhaps the opposite may be true with regard 
to their rates of release and elimination. It may be then 
speculated that these two mechanisms may favor increased 
synthesis and storage of dopamine and increased dissipation 
of norepinephrine in the presence of accumulated acetylcholine. 
It should be pointed out that the acetylcholine-induced 
increase in dopamine in "loaded" rabbits was conspicuous in the 
case of the diencephalon-mesencephalon area, and inconsistent 
and much less pronounced in that of the caudate nucleus. This 
may be related in some way to the high dopamine level in the 
latter compared to the former {cf. Tables 1 and 2). It might 
be considered that since the highest levels of dopamine in the 
brain are found in the caudate nucleus, a much greater 
• 
stimulatory effect upon the dopamine levels is needed by 
acetylcholine to produce a significant dopamine increase, 
the levels of which are already high, compared to the amount 
of stimulation needed by acetylcholine to produce a significant 
dopamine increase in the case of the midbrain-diencephalon, whose 
r 
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levels of dopamine are much lower. Speculatively, it is also 
possible that acetylcholine activation embraces only norepinephrine-
rich neurons in the caudate, and both norepinephrine- and 
dopamine-rich neurons in the midbrain and related areas. 
It is difficult to explain why the responses observed in the 
case of the midbrain-diencephalon are not always observed in 
the case of the caudate nucleus. The above suggestion regarding 
the dopamine levels may serve to provide a possible explan-
ation as to the lack of response to acetylcholine by this 
transmitter in the caudate. With regard to norepinephrine, 
the lack of response to acetylcholine by this amine could be 
due to the fact that norepinephrine levels in the caudate 
nucleus are extremely low, if not almost undetectable. It is 
possible that of the two monoamines in the caudate, dopamine 
serves as the actual transmitter, while norepinephrine serves 
only as a metabolic biproduct formed in the degradation of 
dopamine by dopamine-~-hydroxylase. Still another possibility 
could be that the cholinergic and adrenergic neurons within 
the caudate nucleus might not be compatible for a cholinergic-
adrenergic coupling, i.e. the ~reposed acetylcholine stimual.ted 
interneuron is not present in the caudate nucleus. 
Clarification should be made as to the mechanism by which 
DFP administration produces the elevation in dopamine levels 
and the decrease in norepinephrine levels in the midbrain-
diencephalon, and to a lesser extent in the caudate nucleus. 
; 
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There are three possible explanations of DFP's actions on 
norepinephrine and dopamine. First, DFP as a drug could, 
itself, produce these effects by directly stimulating the 
adrenergic neuron, in a yet unknown manner, producing the 
elevation of dopamine levels, probably through stimulation of 
dopamine synthesis from DOPA, as well as causing the release 
of norepinephrine and a subsequent lowering of the levels 
of this transmitter. Further, these direct actions of DFP 
should be entirely independent of any mediation by acetylcholine, 
whether through DFP stimulation of nearby cholinoceptive 
neurons or interneurons, causing the release of acetylcholine 
which would be indirectly responsible for the actions of DFP 
on both norepinephrine and dopamine levels. The second 
proposed possibility to explain DFP's actions upon norepinephrine 
and dopamine levels relates to an indirect action by DFP. 
This action would be due to acetylcholine, the levels of which 
are elevated by DFP's inhibition of cholinesterases (acetyl-, 
butrylcholinesterase, etc; cf. Methods). Acetylcholine would 
then act on the adrenergic neuron or an interneuron, to cause 
an elevation in dopamine levels, as well as to cause the release 
' 
and lowering of the norepinephrine levels. The third proposed 
possibility concerns the inhibition of dopamine-/.3-hydroxylase 
by DFP or by the accumulated acetylcholine to produce the 
norepinephrine and dopamine responses. 
The results of experiments on the effects of DFP on 
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norepinephrine and dopamine at various intervals following 
DFP (cf. Figures 11 and 12), were interpreted as not supporting 
the third possibility. Had dopamine-~-hydroxylase been 
inhibited by DFP, norepinephrine levels would have continued 
to decrease, and in fact Billiet et al. (1970) found a decrease 
in norepinephrine levels in rabbit caudate nucleus following 
dopamine-a-hydroxylase inhibition. No such effects were 
observed in the present studies. Moreover, by three hours 
both the norepinephrine and the dopamine levels were 
approaching their respective control levels. 
Furthermore, there is no supportive evidence for the 
first possibility, i.e. the direct action of DFP. However, 
supportive evidence does exist with regard to the second 
possibility. The findings that DFP (2.5 mg/kg) caused 
nearly 100 percent inhibition of cholinesterase activity in 
the thalamus, the hypothalamus, the midbrain, and the caudate 
nucleus, as well as the subsequent elevation in the levels 
of acetylcholine levels in these _four brain areas, allow, 
at present, the conclusion that the DFP-induced effects 
upon both norepinephrine and d()pamine, i.e. the elevation in 
dopamine levels and the decrease in norepinephrine levels, 
should be due to the elevated acetylcholine levels resulting 
from DFP inhibition of cholinesterase. 
Consistent with the above proposal is that, cholinoceptive 
neurons and high levels of acetylcholine and acetylcholinesterase 
~ were found by many investigators in the midbrain-diencephalon 
163 
area and in the caudate nucleus {for references, cf. Curtis 
and Crawford, 1969; Karczmar, 1967, 1969, and 1970, as well 
as in the present studies, cf. Tables 3 and 4). Both dopamine 
and norepinephrine are also present in these two areas, dopamine 
being particularly high in the latter {Bertler and Rosengren, 
1959; cf. also Tables 1 and 2). These areas are richly inter-
connected, and the direct dopaminergic nigro-striatal pathway 
{Anden et al., 1966) is particularly important in the present 
context. Cell bodies of both norepinephrine and dopamine 
containing neurons have been shown to originate in the 
mesencephalic {midbrain) region and project rostrally in nerve 
bundles to the striatum {caudate nucleus and putamen) in the 
case of the dopamine containing neurons, and to the diencephalon 
{thalamus and hypothalamus) and telencephalon {cortex) in the 
case of the norepinephrine containing neurons {Anden et al., 1966). 
While many of the pathways in question may be cholinoceptive 
{for references, cf. Silver, 1967; Karczmar, 1970), it is not 
known whether this is also true for the important nigro-striatal 
connection, although recent findings indicate the presence 
of acetylcholinesterase in several important nigro-striatal 
" 
fascicles {Olivier et al., 1970). The presence of both 
cholinoceptive and adrenergic neural pathways in the midbrain-
diencephalon and nigro-striatal regions is supportive of the 
proposal that acetylcholine may induce the observed effects 
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either by activating the catecholamine neurons of the mesen-
cephalon-diencephalon as well as of the striate area (possibly 
via cholinoceptive interneurons, cf. Glisson and Karczmar, 
1970), or via the cholinoceptive participation in the pathways 
which connect these two areas. Of course, DFP administered 
systemically will cause acetylcholine accumulation outside 
of these areas as well, and diffusing or circulating acetyl-
choline, if it should escape cholinesterase, may cause similar 
effects on the monoamines elsewhere in the brain, which then 
would not be due to local, synaptic actions. 
Interesting additional conceptualizations may be offered 
on the basis of the results obtained with the tertiary and 
quaternary atropine. The blocking actions of atropine on the 
acetylcholine-induced norepinephrine depletion and dopamine 
accumulation were not unexpected, and they supported the 
notion of the central site of the acetylcholine action on the 
monoamines. Even without the combined JB835-DOPA pretreatment, 
acetylcholine produced an elevation in dopamine levels and 
a decrement in norepinephrine levels in rabbits receiving 
only JB835, although the augmentation of response was much 
' 
less than that observed after the addition of DOPA. Under these 
conditions, atropine (4.0 mg/kg) blocked nearly completely the 
acetylcholine-induced decrease in norepinephrine. The fact 
that AT.MN was incapable of blocking the norepinephrine depletion 
induced by acetylcholine in the case of the mesencephalon-dien-
cephalon further strengthens this conceptulization. On the 
r 
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other hand, the conspicuous effectiveness of the quaternary 
atropine in blocking the dopamine increase induced by acetyl-
choline (particularly in the case of the diencephalon-mesen-
cephalon area) seems to suggest that the periphery is involved 
also. Indeed, the effects of acetylcholine are not restricted 
to the central nervous system. The two doses of DFP employed 
in this study would produce lethality in at least 50 percent 
of the rabbits in a 24 hour period (cf. Karczmar, 1967}, and 
they are capable of inducing marked peripheral effects which 
in the rabbit are of the muscarinic nature (cf. Holmstedt, 
1959). These effects are readily blocked by the quaternary 
atropinics, although the tertiary mother compound may be 
expected to antagonize them to an extent also. It may be 
speculated that, in the "loaded" animals the acetylcholine-
induced increase in dopamine levels- and in the rate 
of its synthesis- may depend ontheir peripheral actions and the 
more marked action of ATMN may be due to its particular 
effectiveness at the parasympathetic periphery. Moreover, 
atropine at a higher dose (4.0 mg/kg), given to rabbits pre-
treated with JB835, was able to produce a more marked block of 
' 
the acetylcholine-induced elevation in dopamine levels than 
at the lower (2.0 mg/kg) dose in the JB835-DOPA treated animals; 
the block produced by the higher dose of atropine closely 
resembled the block of the acetylcholine-induced dopamine 
'·· elevation seen with the ·administration of ATMN ( 2. 0 mg/kg}, 
l 
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indicating atropine's peripheral effectiveness in blocking 
the acetylcholine-induced elevation in the dopamine levels, 
provided doses greater than those of ATMN needed to produce 
this block are used. On the other had, as atropine, but 
not the quaternary atropine affected the acetylcholine-induced 
changes in norepinephrine in the "loaded" animals, this 
particular mechanism may be entirely central in its location. 
On the basis of these findings, a working neural model 
was constructed to explain the effects of acetylcholine on the 
central norepinephrine and dopamine levels (Figure 27). 
It is proposed that administration of DFP leads to the 
accumulation of acetylcholine within the central and auto-
nomic nervous systems by inhibiting the activity of cholin-
esterases. Further inventigations may, in fact, show that 
acetylcholinesterase is the cholinesterase particularly involved. 
Centrally, acetylcholine, acting either through an interneuron 
(labelled (1) in the figure) or directly through cholinoceptive 
sites on the adrenergic neuron (labelled (2) in the figure) 
causes the release of norepinephrine from the adrenergic 
terminals. In addition, perip(leral effects of acetylcholine, 
relayed via the afferent pathways to the adrenergic neuron, 
cause the elevation in dopamin:! levels, probably through 
stimulation of the synthesis of dopamine from DOPA. The effect 
postulated to depend on the stimulation of,sensory afferents 
by the accumulation of acetylcholine, is not, at present, well 
r 
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FIGURE 27 Hypothetical model of central cholinergic involve-
ment in adrenergic nerve transmission. 
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understood. The data indicate that it is sensit!_ve to the 
blocking actions of AT.MN and AtSO (cf. below for further 
4 
discussion) • 
It was apparent that the most prominent effects of acetyl-
choline upon the norepinephrine and the dopamine levels occurred 
in the midbrain-diencephalon. The additional studies demon-
strated that the acetylcholine-induced elevation in dopamine 
levels and decrease in norepinephrine levels was wide-spread, 
as it occurred in the midbrain, the thalamus, the hypothalamus, 
and also in the non-midbrain-diencephalon area, the hippo-
campus. These data were very much in agreement with findings 
obtained with regard to the midbrain-diencephalon region. 
In addition, it was found that ATMN blocked the elevation 
of the dopamine levels within these four brain areas, but was 
ineffective in preventing the acetylcholine-induced decrease 
in norepinephrine levels. This suggests that the sensory 
afferents, i.e. the lateral spinothalamic tract,· are in close 
contact with the adrenergic neurons of the individual areas. 
Supportive of this concept is the fact ~hat sensory afferents 
from the lateral spinothalamic tract are reported to distribute 
' 
through the reticular formation and thalamus from which branching 
collaterals arise invading these regions. Moreover, various 
peripheral sensory receptors, i.e. pain, touch, etc., are 
reported to be stimulated by acetylcholine (personal communication, 
R. Wurster). Additional evidence of widespread sensory influence 
r 
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comes from EEG and evoked potential experiments in which 
enviromental stimuli, i.e. sound, pain, light, often trigger 
widespread central alerting (Himwich, 1962}. 
To expand further upon this point, one might conclude that 
the cholinergically mediated peripheral influence upon the 
central nervous system reflected in the effect upon dopamine 
levels- could well be one of the mechanisms by which behavorial 
stresses act to influence central responses. In ·fact, it is 
most probable that the same sensory afferents are involved-
in both the acetylcholine- and the stress-induced effects 
upon the central nervous system. The question which remains 
to be answered is whether certain types of stressful conditions 
produce similar effects, as acetylcholine does, upon the 
dopamine levels. 
Principal criticism of the studies purporting to show central 
drug responses such as these is that the drugs, particularly 
DFP, were administered via a peripheral route. Such routes of 
administration allow for stimulation of peripheral sites which 
contribute to, or modify, the central effect of the drug. 
This type of contribution was observed in these studies with 
' 
regard to the ATMN sensitive, acetylcholine-induced elevation 
in dopamine levels. By using the quaternary atropinic, AT.MN, 
it was attempted to demonstrate those responses to acetylcholine 
"Which were central in origin, as AT.MN was reportedly unable 
-to pass through the blood brain barrier at the dose used, 
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2.0 mg/kg (Albanus, 1970). However, it was possible that 
peripheral sites other than those blocked by AT.MN also 
contributed to the central actions of acetylcholine, although 
such additional actions of acetylcholine seemed remote. 
Nevertheless, demonstration of the central actions of acetyl-
choline divorced from any peripheral influence was necessary 
if contribution to acetylcholine's central actions by non-
ATMN sensitive sites was to be ruled out. 
The results of the intraventricular injection of DFP indicated 
that norepinephrine was released by this mechanism and these 
results obtained following the intraventricular DFP administration 
resembled those due to s.c. DFP. On the other hand, there 
was an absence of any elevation in dopamine levels, contrary 
to the response to s.c. administered DFP. That no dopamine 
elevation occurred in these experiments, indicates an extra-
central mechanism. Further, AT.MN given prior to the intra-
ventricular injection of DFP had no effect on dopamine levels, 
compared to the ability of AT.MN to block the acetylcholine-
induced elevation of dopamine levels when DFP was administered 
via the s.c. route. 
' 
Thus, it would appear that the central effects of acetyl-
choline on the central monoamine levels could be divorced 
from those actions of acetylcholine which are peripherally 
mediated. Moreover, the possibility of acetylcholine stimulating 
the ATMN-insensitive peripheral sites, which could contribute 
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to the acetylcholine-induced release of norepinephrine, can 
be eliminated. Had the acetylcholine-induced release of 
norepinephrine been due to such peripheral stimulation of 
AT.MN-insensitive sites, then lowering of the norepinephrine 
levels would not have been observed following the intra-
ventricular injection of DFP. As such, a lowering of the 
norepinephrine levels was observed, a central rather than 
peripheral mechanism may be suggested for this action of 
acetylcholine. 
Before drawing final conclusions, mention should be made of 
the many other uninvestigated, but not forgotten, mechanisms 
which might have been involved. The possibility of acetyl-
choline actions on enzyme systems such as catechol-0-methyl 
transferase and/or DOPA decarboxylase exists. Similarly, 
turnover studies of norepinephrine and dopamine would lend 
additional understanding to the observed responses, as would 
evoked potential and fluorescence microscopy studies. The 
possibility of other transmitter involvement, i.e. serotonin, 
tryptamine, histamine, is very real. It is impossible to 
investigate all possibilities tin a single dissertation, but 
hopefully it will inspire additional investigations. 
,. 
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SUMMARY 
In the thalamus, the hypothalamus, the midbrain, and the 
caudate nucleus in rabbit brain, DFP (2.5 mg/kg) was found 
to cause nearly 100 percent inhibition of cholinesterase 
activity. In addition, pretreatment of the animals with JB835-
DOPA cornpinations had no effect upon cholinesterase activity 
in these four brain areas compared to cholinesterase activity 
in identical brain areas of control (no drug) animals, indicating 
that the monoamines norepinephrine and dopamine, elevated by the 
pretreatment, are not active on this enzyme system. 
Data was also presented showing that acetylcholine levels 
in the thalamus, the hypothalamus, the midbrain, and the 
caudate nucleus in rabbit brain were elevated more than 100 
percent over appropriate control acetylcholine levels by this 
dose of DFP (2.5 mg/kg}. Of importance was the finding that 
elevated norepinephrine and dopamine levels were without 
effect upon the acetylcholine levels, indicating that adrenergic 
actions upon cholinoceptive nebrons do not exist in these 
rabbit brain parts. 
Studies were subsequently carried out to demonstrate the 
central effects induced by the elevated central levels of 
acetylcholine as a result of cholinesterase inhibition by DFP. 
173 
Data were presented which link peripheral administration of 
DFP and the subsequent elevation in acetylcholine levels to 
a significant decrement of central norepinephrine in the midbrain-
diencephalon, and·· to some extent in the caudate nucleus. These 
findings are supported by evidence of identical responses 
occurring in the midbrain, the thalamus, the hypothalamus, 
and the hippocampus due to acetylcholine. 
Dopamine levels, unlike norepinephrine levels, were significantly 
elevated in the midbrain-diencephalon by acetylcholine and to 
a lesser extent in the caudate ~ucleus. Acetylcholine induced 
a similar effect on dopamine levels in the midbrain, the thalamus, 
the hypothalamus, and the hippocampus. Interestingly, however, 
acetylcholine's actions on dopamine and on norepinephrine occurred 
only following pretreatment with JB835, DOPA, or the JB835 and 
DOPA-combination; this suggests that acetylcholine's actions 
are best observed under optimal conditions for monoamine storage 
and synthesis. Yet, acetylcholine may induce less pronounced 
changes under less favorable conditions as well. 
Additional conceptulizations were offered on the basis of 
the results obtained· with the tertiary and quaternary atropine. 
The blocking actions of atropine on the acetylcholine-induced 
norepinephrine depletion and dopamine accumulation were not 
unexpected, and they supported the notion of the central site 
of action of acetylcholine. The fact that ATMN was incapable 
of blocking the norepinephrine depletion induced by acetylcholine 
r 
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in the case of the midbrain-diencephalon, further strengthens 
this conceptulization. However, the ability of ATMN to 
block the dopamine accumulation induced by acetylcholine 
suggested peripheral rather than central involvement for 
this action. 
DFP (200µg) injected intraventricularly into rabbits caused 
a decrease in norepinephrine levels in the midbrain-diencephalon 
which ATMN was unable to block. Significant accumulation of 
dopamine in the midbrain-diencephalon was not, however,_ observed 
following intraventricular injections of DFP: nor did AT.MN 
produce any significant effects on dopamine levels. 
The conclusions arrived at from these studies led to the 
postulation of a neural model to explain the elevation in dopamine 
levels and the decrease in norepinephrine levels resulting from 
the accumulation of acetylcholine, resulting from DFP's inhibition 
of cholinesterase activity in rabbit brain. 
It is proposed, based upon data obtained in these experiments, 
that elevated central acetylcholine levels, resulting from 
DFP's inhibition of cholinesterase activity, acts either 
through an interneuron or dir~ctly through cholinoceptive 
sites on the adrenergic neuron to cause the release of 
norepinephrine. In addition, DFP-induced elevation of acetyl-
choline leads through stimulation of the atropine and AT.MN 
sensitive sites, to an elevation of the dopamine levels, 
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probably through stimulation of the synthesis of dopamine 
from DOPA. 
Under the experimental conditions employed in these studies, 
neurochemical evidence of cholinergic-adrenergic coupling 
phenomena was thus demonstrated. The role of such a mechanism 
is, however, unclear. 
It is hopeful that these observations will provide a 
foundation upon which future investigations of the cholinergic-
adrenergic linkage will begin. 
' 
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